<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12473165</article-id><article-id pub-id-type="pmcid-ver">PMC12473165.1</article-id><article-id pub-id-type="pmcaid">12473165</article-id><article-id pub-id-type="pmcaiid">12473165</article-id><article-id pub-id-type="pmid">41012550</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17091215</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-01215</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Theranostic Potential of a New <sup>64</sup>Cu-Labeled NOTA-R954 Peptide Conjugate for Kinin B1R Expressing Prostate Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ghanaatgar Kasbi</surname><given-names initials="S">Sadaf</given-names></name><xref rid="af1-pharmaceutics-17-01215" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-01215" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Savard</surname><given-names initials="M">Martin</given-names></name><xref rid="af1-pharmaceutics-17-01215" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-01215" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7785-5881</contrib-id><name name-style="western"><surname>Couture</surname><given-names initials="F">Fr&#233;d&#233;ric</given-names></name><xref rid="af3-pharmaceutics-17-01215" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dubuc</surname><given-names initials="C">C&#233;l&#233;na</given-names></name><xref rid="af1-pharmaceutics-17-01215" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-01215" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dumulon-Perreault</surname><given-names initials="V">V&#233;ronique</given-names></name><xref rid="af4-pharmaceutics-17-01215" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0936-6618</contrib-id><name name-style="western"><surname>Nepveu-Traversy</surname><given-names initials="ME">Marie-Edith</given-names></name><xref rid="af1-pharmaceutics-17-01215" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-01215" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ait-Mohand</surname><given-names initials="S">Samia</given-names></name><xref rid="af4-pharmaceutics-17-01215" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sabbagh</surname><given-names initials="R">Robert</given-names></name><xref rid="af5-pharmaceutics-17-01215" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Geha</surname><given-names initials="S">Sameh</given-names></name><xref rid="af6-pharmaceutics-17-01215" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0319-4512</contrib-id><name name-style="western"><surname>Gu&#233;rin</surname><given-names initials="B">Brigitte</given-names></name><xref rid="af2-pharmaceutics-17-01215" ref-type="aff">2</xref><xref rid="af4-pharmaceutics-17-01215" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4758-1589</contrib-id><name name-style="western"><surname>Dory</surname><given-names initials="Y">Yves</given-names></name><xref rid="af7-pharmaceutics-17-01215" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gobeil</surname><given-names initials="F">Fernand</given-names></name><xref rid="af1-pharmaceutics-17-01215" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-01215" ref-type="aff">2</xref><xref rid="c1-pharmaceutics-17-01215" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Calienni</surname><given-names initials="MN">Maria Natalia</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Moretton</surname><given-names initials="MA">Marcela Analia</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-01215"><label>1</label>Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Universit&#233; de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada; <email>sadaf.ghanaatgar-kasbi@usherbrooke.ca</email> (S.G.K.); <email>martin.savard@usherbrooke.ca</email> (M.S.); <email>celena.dubuc@usherbrooke.ca</email> (C.D.); <email>marie-edith.nepveu-traversy@usherbrooke.ca</email> (M.-E.N.-T.)</aff><aff id="af2-pharmaceutics-17-01215"><label>2</label>Institute of Pharmacology, Faculty of Medicine and Health Sciences, Universit&#233; de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada; <email>brigitte.guerin2@usherbrooke.ca</email></aff><aff id="af3-pharmaceutics-17-01215"><label>3</label>TransBIOTech, L&#233;vis, QC G6V 6Z3, Canada; <email>frederic.couture@tbt.qc.ca</email></aff><aff id="af4-pharmaceutics-17-01215"><label>4</label>Department of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Universit&#233; de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada; <email>veronique.dumulon-perreault@usherbrooke.ca</email> (V.D.-P.); <email>samia.ait-mohand@usherbrooke.ca</email> (S.A.-M.)</aff><aff id="af5-pharmaceutics-17-01215"><label>5</label>Department of Surgery, Division of Urology, Universit&#233; de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada; <email>robert.sabbagh@usherbrooke.ca</email></aff><aff id="af6-pharmaceutics-17-01215"><label>6</label>Department of Pathology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada; <email>sameh.geha@usherbrooke.ca</email></aff><aff id="af7-pharmaceutics-17-01215"><label>7</label>Department of Chemistry, Faculty of Sciences, Universit&#233; de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada; <email>yves.dory@usherbrooke.ca</email></aff><author-notes><corresp id="c1-pharmaceutics-17-01215"><label>*</label>Correspondence: <email>fernand.gobeil@usherbrooke.ca</email>; Tel.: +1-(819)-821-8000 (ext. 72378)</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>17</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">497664</issue-id><elocation-id>1215</elocation-id><history><date date-type="received"><day>04</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>08</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>27</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-17-01215.pdf"/><abstract><p><bold>Background/Objectives</bold>: This study explores the potential of the inducible G protein-coupled kinin B1 receptor (B1R) as a target for the diagnosis and treatment of prostate cancer (PCa) and aims to develop the first theranostic agent targeting hB1R for both molecular imaging and radionuclide therapy. <bold>Methods</bold>: B1R expression was analyzed via qPCR and immunohistochemistry in human PCa cells and tissues specimens. A novel <sup>64</sup>Cu/NOTA-conjugated peptide analog of the potent B1R antagonist R954 was synthetized and evaluated in vitro and in vivo. <bold>Results</bold>: B1R was confirmed to be expressed (RNA, protein) by varying degrees in all PCa cell lines and tissues investigated, with protein level significantly correlating with tumor grades. This finding was supported by similar analyses from the TCGA and MSKCC databases. In vitro, the <sup>64</sup>Cu/NOTA-&#946;Ala-R954 conjugate showed nanomolar affinity/potency at hB1R, complete plasma stability over 24 h, significant cellular uptake (up to 33% of ID at 24 h), and dose-dependent anti-clonal growth effects. In vivo, the radioconjugate remained stable in circulation for up to 90 min and was primarily excreted intact via the kidneys following IV administration. Intravenous <sup>64</sup>Cu/NOTA-&#946;Ala-R954 (7.5 MBq) effectively detected subcutaneous PCa xenografts via &#181;PET imaging in male athymic nude mice. At a single higher dose (65 MBq; 50 &#181;g/kg), it significantly reduced tumor growth without observable toxicity. This antitumor effect was associated with increased apoptosis (active caspase-3) and reduced proliferation (Ki67), as shown by immunohistochemistry. In contrast, the nonradioactive <sup>Nat</sup>Cu/NOTA-&#946;Ala-R954 had no therapeutic effect at the same dose. <bold>Conclusions</bold>: Our findings provide proof-of-concept for the potential theranostic use of <sup>64</sup>Cu/NOTA-R954 in PCa, and potentially other types of B1R-positive solid cancers.</p></abstract><kwd-group><kwd>kinins</kwd><kwd>GPCR B1 receptor</kwd><kwd>peptide antagonist</kwd><kwd>theranostics</kwd><kwd>prostate cancer</kwd></kwd-group><funding-group><award-group><funding-source>Movember Discovery Grant from Prostate Cancer Canada</funding-source><award-id>D2014-15</award-id></award-group><award-group><funding-source>Canadian Institutes of Health Research</funding-source><award-id>MOP-166037</award-id></award-group><award-group><funding-source>Fonds de Recherche du Qu&#233;bec Sant&#233; (FRQS)-funded Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS)</funding-source></award-group><funding-statement>This project was funded by Movember Discovery Grant from Prostate Cancer Canada (Grant number D2014-15) and the Canadian Institutes of Health Research Grant (MOP-166037). R.S., S.G., Y.D., B.G., and F.G. are members of the Fonds de Recherche du Qu&#233;bec Sant&#233; (FRQS)-funded Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-01215"><title>1. Introduction</title><p>Prostate cancer (PCa) is the most common non-skin cancer and the second leading cause of cancer deaths among men in North America [<xref rid="B1-pharmaceutics-17-01215" ref-type="bibr">1</xref>]. In Canada, approximately 1 in 8 men will be diagnosed with PCa during their lifetime, and 1 in 30 cases will result in death [<xref rid="B2-pharmaceutics-17-01215" ref-type="bibr">2</xref>]. Despite advances in diagnosis and treatment, mortality rates remain high for locally advanced (stage III) and metastatic (stage IV) cases, highlighting the need for improved therapies, early detection, and precise staging. Evidence indicates that timely and accurate diagnosis significantly improves prognosis, with early intervention before metastasis markedly increasing the 5-year survival rate [<xref rid="B1-pharmaceutics-17-01215" ref-type="bibr">1</xref>]. However, PCa is one of the few cancers not well detected by conventional <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (PET) imaging, due to its low metabolic activity [<xref rid="B3-pharmaceutics-17-01215" ref-type="bibr">3</xref>]. Thus, continuous innovation in diagnostic tools and therapeutic strategies remains essential to reducing the burden of advanced disease.</p><p>Currently, PCa screening relies on serum prostate-specific antigen (PSA) measurements and digital rectal examination (DRE), both of which have limited sensitivity and specificity [<xref rid="B4-pharmaceutics-17-01215" ref-type="bibr">4</xref>]. When clinical suspicion persists, magnetic resonance imaging (MRI) and targeted biopsies may improve diagnostic accuracy. Nevertheless, developing reliable, non-invasive detection methods remains a critical challenge [<xref rid="B5-pharmaceutics-17-01215" ref-type="bibr">5</xref>].</p><p>In this regard, a promising non-invasive approach to enhancing PCa screening across various stages is the use of targeted molecular imaging and radiotherapy through theranostics. These innovative agents combine diagnostic and therapeutic capabilities within a single molecule. Unlike traditional non-selective chemotherapy, theranostics enable precise identification of patients whose tumors express specific molecular targets, facilitating personalized treatment and predicting a more favorable response to radiation therapy [<xref rid="B6-pharmaceutics-17-01215" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-17-01215" ref-type="bibr">7</xref>].</p><p>Peptide-activated G protein-coupled receptors (GPCRs) are attractive biomarker targets for developing cancer theranostics due to their overexpression on cancer cell surfaces and their role in regulating key cellular processes critical for cancer, such as proliferation, apoptosis, migration, chemoresistance, angiogenesis, immune invasion, and metastasis [<xref rid="B8-pharmaceutics-17-01215" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-17-01215" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-17-01215" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-17-01215" ref-type="bibr">11</xref>]. However, to date, only a limited set of GPCR-targeted peptidic theranostics (e.g., analogs of somatostatin, vasointestinal peptide, and bombesin/gastrin-releasing peptides) have been developed for detecting and treating PCa, and their clinical applicability is currently under investigation [<xref rid="B12-pharmaceutics-17-01215" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-17-01215" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-17-01215" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-01215" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-01215" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-17-01215" ref-type="bibr">17</xref>]. In this context, the kinin B1 receptor (B1R) emerges as a highly promising target for theranostic applications. B1R overexpression is common in many human solid cancers, including PCa, contributing to the growth, migration, and invasion of cancer cells; see comprehensive reviews [<xref rid="B18-pharmaceutics-17-01215" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-17-01215" ref-type="bibr">19</xref>]. Studies have shown that exogenous stimulation of B1R by kinin desArg<sup>9</sup>-metabolites (linear peptides) increases the proliferation and migration of both androgen-sensitive and -insensitive human PCa cells in vitro [<xref rid="B18-pharmaceutics-17-01215" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-17-01215" ref-type="bibr">19</xref>]. Moreover, peptide B1R antagonists have been effective in inhibiting PCa cell growth both in vitro and in vivo in tumor-bearing nude mice [<xref rid="B20-pharmaceutics-17-01215" ref-type="bibr">20</xref>]. Notably, B1R has minimal roles in normal physiology [<xref rid="B21-pharmaceutics-17-01215" ref-type="bibr">21</xref>] and is induced by tumor-associated inflammation, reducing potential side effects. A pilot clinical study on a limited number of PCa biopsy specimens (16 cases) suggested a correlation between B1R expression and the onset of PCa [<xref rid="B22-pharmaceutics-17-01215" ref-type="bibr">22</xref>]. B1R may, thus, be a prime candidate for PCa detection and targeted radiotherapy, using techniques like PET and novel biostable radiolabeled kinin B1R peptide analogs.</p><p>The main objectives of the study were to further investigate the clinical importance of B1R as a biomarker and therapeutic target for PCa using molecular profiling of relevant in vitro human PCa cell lines and clinical samples, and to evaluate the theranostic potential of a new radiopeptide targeting B1R for PCa detection and therapy. For this purpose, we employed our optimized lead peptide B1R antagonist, AcOrn[Oic<sup>2</sup>,<sup>(&#945;Me)</sup>Phe5,<sc>d</sc>&#946;Nal<sup>7</sup>,Ile<sup>8</sup>]desArg<sup>9</sup>-bradykinin (codenamed R954), which was identified through structure&#8211;activity relationship studies and exhibits excellent potency, selectivity, specificity, and stability [<xref rid="B23-pharmaceutics-17-01215" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-17-01215" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-17-01215" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-01215" ref-type="bibr">26</xref>]. Among medical radionuclides, we selected the isotope <sup>64</sup>Cu due to its growing recognition for theranostic applications in recent years, attributed to its unique decay properties that are well-suited for both PET imaging (t<sub>1/2</sub>= 12.7 h; &#946;<sup>+</sup>, 0.65 MeV [17.8%]) and endoradiotherapy (&#946;<sup>&#8722;</sup>, 0.58 MeV [38.4%], Auger electrons [43.5%]) [<xref rid="B27-pharmaceutics-17-01215" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-01215" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-01215" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-01215" ref-type="bibr">30</xref>]. In addition, our cyclotron facility, equipped with a PET imaging center, supplies this radionuclide on a biweekly basis at a high apparent molar activity (333&#8211;444 TBq/mmol). The selected in vitro and in vivo models were based on two human B1R-expressing PCa cell lines: LNCap and PC3 cells; these cell lines represent androgen-dependent and castration-resistant forms of PCa, respectively, and are widely used in preclinical studies to model hormone-sensitive and advanced, treatment-resistant diseases.</p><p>In this study, we present new evidence regarding the clinical utility of B1R as a biomarker for PCa therapy. We also demonstrate the efficacy of the newly designed B1R radioantagonist <sup>64</sup>Cu/NOTA-&#946;Ala-R954 in targeting and limiting the growth of experimental PCa, highlighting its potential for future research in cancer theranostics.</p></sec><sec id="sec2-pharmaceutics-17-01215"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-01215"><title>2.1. Antibodies</title><p>Antibodies and their respective sources (in parentheses) are listed as follows: anti-active (cleaved) caspase-3 antibody (Cell Signaling Technology; 5A1, Danvers, MA, USA); anti-Ki67 antibody (Abcam; ab15580, Waltham, MA, USA); anti-CD34 antibody (Abcam; ab81289); anti-LYVE1 antibody (Abcam; ab14917); anti-nuclear pore complex antibody (Abcam; ab24609); anti-Na+/K+ ATPase &#945; antibody (Santa Cruz Biotechnology; SC-28800, Dallas, TX, USA); anti-clathrin HC antibody (Santa Cruz Biotechnology; SC-58714); and anti-lamin A/C antibodies (Santa Cruz Biotechnology; SC-56139); anti-cytochrome C antibody (BD Biosciences; 556433, San Jose, CA, USA); anti-tubulin antibody (Sigma-Aldrich; T9026, Burlington, MA, USA); anti-LAMP-2 antibody (DSHB University of Iowa; clone H4B4, Iowa City, IA, USA); anti-calnexin antibody (Abcam; ab2798); rabbit anti-human B1R polyclonal (C-terminus) antibody LS-A799 (LifeSpan Biosciences Inc., Seattle, WA, USA); rabbit anti-human B1R antiserum AS434 targeting 6 distinct epitopes on the extra- and intracellular domains of B1R (donated by Dr W Muller-Esterl) [<xref rid="B31-pharmaceutics-17-01215" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-01215" ref-type="bibr">32</xref>]; non-immunized rabbit immunoglobulin fraction (Agilent Technologies, Santa Clara, CA, USA); goat anti-mouse and anti-rabbit HRP-conjugated secondary antibodies (Sigma-Aldrich and AbD-Serotec, Raleigh, NC, USA, respectively); and Alexa-488 conjugated anti-rabbit antibody (Molecular Probe, Life Technology, Eugene, OR, USA). Target specificity of the two anti-B1R antibodies LS-A799 and AS434 has been reported elsewhere [<xref rid="B31-pharmaceutics-17-01215" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-01215" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-01215" ref-type="bibr">33</xref>] and has been further established herein by demonstrating relatively higher staining intensities obtained with these two primary antibodies in human embryonic kidney 293 cells (HEK293) stably transfected with human B1R in comparison with mock-transfected cells, as assessed by epifluorescence microscopy (see <xref rid="app1-pharmaceutics-17-01215" ref-type="app">Supplementary Figure S1</xref>).</p></sec><sec id="sec2dot2-pharmaceutics-17-01215"><title>2.2. Tissue Microarray (TMA) Construction and Immunohistochemical (IHC) Analysis</title><p>Formalin-fixed paraffin-embedded (FFPE) archived prostate specimens from patients who underwent radical prostatectomy between 2006 and 2011 at the Centre Hospitalier Universitaire de Sherbrooke were used. Patients consented to participate and signed a consent form. The research protocol was approved by the Institutional Review Committee for the Use of Human Resected Material at the Centre Hospitalier Universitaire de Sherbrooke (approval #10-017). This study was conducted in accordance with the Declaration of Helsinki and approved by the Human Ethics Committee at the Centre de Recherche du CHUS (Protocol #2013-490; 24 October 2012), Sherbrooke. Consent to use paraffin-embedded prostate tissue specimens for the current study was obtained through telephone interviews from all subjects or their families, with appropriate written documentation.</p><p>For each prostate tissue, duplicate cores (1.5 mm diameter of both tumor primary pattern and secondary pattern as well as prostatic intraepithelial neoplasia (PIN) and normal prostate glandular tissues) were extracted from donor blocks and inserted into a new paraffin block. The nature of each core was confirmed by hematoxylin&#8211;eosin (H&amp;E) staining and examined by an expert uropathologist (SG). One case of metastatic PCa obtained by fine needle aspiration of peripancreatic ganglia was also included in the study.</p><p>TMA sections (4 &#181;m) were deparaffinized and stained with the anti-B1R antibody LS-A799 (1:400) using a Dako streptavidin&#8211;biotin-based automated stainer (Agilent Technologies, Santa Clara, CA, USA), and counterstained with hematoxylin. Stained sections were scanned in brightfield using the Hamamatsu Nanozoomer 2.0-RS whole slide scanner (Hamamatsu Corporation, Bridgewater, NJ, USA) and images exported with Nanozoomer Digital Pathology (NDP) view 2 imaging software (version 2.6.13; Hamamatsu Corporation. Images were then analyzed by 2 independent observers (FC and SG) using a pre-established scale for staining evaluation (see <xref rid="app1-pharmaceutics-17-01215" ref-type="app">Supplementary Figure S2</xref>). Each core was scored individually and the highest scores from duplicates by each observer were used to calculate the average immuno-score.</p></sec><sec id="sec2dot3-pharmaceutics-17-01215"><title>2.3. Fresh Tissue Dissection and RNA Isolation</title><p>Prostate tissues used for RNA extraction were freshly (typically within 30 min) dissected from prostate specimens obtained from radical prostatectomies performed at the Centre Hospitalier Universitaire de Sherbrooke. The tissues were frozen at &#8722;20 &#176;C with OCT compound (Tissue-Tek; Miles Scientific, Elkhart, IN, USA). Sections of 5 &#181;m were cut and fixed in formalin for H&amp;E staining to enable pathological examination. Tumor regions were delineated along with adjacent non-cancerous tissues by a clinical pathologist, and dissection was performed accordingly. The dissected tissues were washed with nano-pure RNase-free water (Wisent Inc., Saint-Jean-Baptiste, QC, Canada) to remove any visible traces of the OCT compound. The tissues were then finely ground in liquid nitrogen, and RNA was extracted using QIAGEN RNeasy spin columns (QIAGEN, Toronto, ON, Canada) according to the manufacturer&#8217;s instructions. RNA integrity (200 ng total) was assessed by agarose gel electrophoresis.</p></sec><sec id="sec2dot4-pharmaceutics-17-01215"><title>2.4. Expression and Survival from Databases</title><p>Expression levels of BDKRB1 and survival data were retrieved using cBioportal in the datasets: TCGA Prostate Adenocarcinoma (Previously known as TCGA Provisional) and MSKCC Cancer Cell 2010 [<xref rid="B34-pharmaceutics-17-01215" ref-type="bibr">34</xref>]. For TCGA RNA-Seq data, a Z-score compared to diploid cells of 1.75 was used to distinguish high (altered) from low expressor (unaltered). For MSKCC microarray data, a z-score from mRNA expression values of 2.25 was used.</p></sec><sec id="sec2dot5-pharmaceutics-17-01215"><title>2.5. Cell Cultures</title><p>The PCa cell lines LNCaP (AR+/PSA+/p53wt), PC3 (AR-/PSA-/p53null), CWR22Rv1 (AR+/PSA+/p53mutated), and DU145 (AR-/PSA-/p53mutated) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). PCa cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS, Wisent Inc.) + 1% penicillin/streptomycin (Pen/Strep) and were maintained in a humidified 5% CO<sub>2</sub> environment at 37 &#176;C. The cells were passaged and collected using 0.05% trypsin/EDTA (Wisent Inc.) or StemPro Accutase<sup>&#174;</sup> solution (Life Technologies, Carlsbad, CA, USA). PCa cell lines were routinely screened for mycoplasma contamination using PCR-based detection methods. Initially, regular testing was performed with the Universal Mycoplasma Detection Kit from ATCC to confirm the absence of contamination. Subsequently, the cell lines were periodically verified at the RNomic platform of Universit&#233; de Sherbrooke using the IVM Biotech Mycoplasma PCR Detection Kit (Cat. No. MDK001; IVM Biotech, Longueil, QC, Canada). Stable puromycin-resistant human embryonic kidney cells (QBI-HEK293A) overexpressing human B1R or B2R, achieved through lentiviral-mediated transduction, were cultured in Dulbecco&#8217;s modified Eagle&#8217;s medium (DMEM) supplemented with 10% of FBS and 1% Pen/Strep and passaged, as indicated above.</p></sec><sec id="sec2dot6-pharmaceutics-17-01215"><title>2.6. RNA Extraction and Quantitative Real-Time PCR Analysis</title><p>Total RNAs from human PCa cell lines and PCa tissues were isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer&#8217;s instructions. Genomic DNA was removed from total RNA using RNase-Free DNase (Qiagen). RNA integrity was assessed with a TapeStation System (Agilent Technologies). Then, 0.5 to 2 &#181;g of total RNA was subjected to reverse transcription using Oligo-dT primers and Superscript III transcriptase (Invitrogen). Quantitative real-time PCR (qRT-PCR) was conducted on a MX3005p Stratagene instrument (Agilent technologies) or on a CFX OPUS-384 system (Bio-Rad, Hercules, CA, USA) with Brilliant III SYBR green (Agilent technologies). Primers used were B1R sense, 5&#8242;-CTTTTGGGAGGACTTCATTGAC-3&#8242;; antisense, 5&#8242;-GGGATGAAGATATTGGAGCAAG-3&#8242;; &#946;-actin sense, 5&#8242;-GTTGCTATCCAGGCTGTGCTA- 3&#8242;; antisense, 5&#8242;-GCGGATGTCCACGTCACACTT-3&#8242;. Relative mRNA expression was analyzed with the comparative Ct method (2<sup>&#8722;&#8710;&#8710;CT</sup>) and normalized to &#946;-Actin as an internal reference gene.</p></sec><sec id="sec2dot7-pharmaceutics-17-01215"><title>2.7. Gene Expression Analysis of CDX Models Using Affymetrix<sup>&#174;</sup> HG-U133 Plus 2.0 Arrays</title><p>B1R gene expression analysis of the human PCa cell line-derived xenografts (four CDX models) in Nu/Nu mice was conducted by Charles River custom services (Freiburg, Germany) [<xref rid="B35-pharmaceutics-17-01215" ref-type="bibr">35</xref>]. For mRNA preparation, tumors were grown in untreated mice until they reached a size of 400&#8211;800 mm<sup>2</sup>. Following sacrifice, tumors were immediately excised, and tumor pieces free of necrosis were flash-frozen in liquid nitrogen. Following mechanical tissue disruption, total tumor RNA was extracted using the RNeasy Mini kit (QIAGEN). Gene expression profiles were obtained by Affymetrix HGU133plus2 microarray chips (Thermo Fisher Scientific, Waltham, MA, USA). Expression values were extracted from CEL files and calculated and log 2 transformed using R/Bioconductor packages (gcRMA).</p></sec><sec id="sec2dot8-pharmaceutics-17-01215"><title>2.8. Production of 64Cu</title><p>Copper-64 (<sup>64</sup>Cu) was prepared on a TR-19 or a TR-24 cyclotron (ACSI) via the <sup>64</sup>Ni(p,n)<sup>64</sup>Cu reaction, using an enriched <sup>64</sup>Ni target electroplated on a rhodium disc. The [<sup>64</sup>Cu]CuCl<sub>2</sub> was recovered from the target following the procedure of McCarthy et al. [<xref rid="B36-pharmaceutics-17-01215" ref-type="bibr">36</xref>] and subsequently converted to [<sup>64</sup>Cu]Cu(OAc)<sub>2</sub> by dissolving the [<sup>64</sup>Cu]CuCl<sub>2</sub> in ammonium acetate (0.1 M; pH 5.5).</p></sec><sec id="sec2dot9-pharmaceutics-17-01215"><title>2.9. Peptide Synthesis and NOTA Conjugation</title><p>The peptide R954 was synthesized on a Symphony-X peptide synthesizer (Protein Technologies, Inc., Tucson, AZ, USA) using 9-fluorenylmethyloxycarbonyl (Fmoc) chemistry [<xref rid="B31-pharmaceutics-17-01215" ref-type="bibr">31</xref>,<xref rid="B37-pharmaceutics-17-01215" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-17-01215" ref-type="bibr">38</xref>]. The bifunctional NOTA chelator (1,4,7-triazacyclononane-1,4,7-triacetic acid) was conjugated to the N-terminal of the deacetylated R954 sequence, which had been previously extended with a non-natural, non-cleavable &#946;-Ala linker residue to mitigate steric hindrance in B1R ligand binding [<xref rid="B38-pharmaceutics-17-01215" ref-type="bibr">38</xref>]. The purity and identity of purified peptides were evaluated using ultraperformance liquid chromatography&#8211;tandem mass spectrometry (UPLC-UV-MS, Waters AQUITY-H-Class-SQD2; Waters Corporation, Milford, MA, USA) (see <xref rid="app1-pharmaceutics-17-01215" ref-type="app">Supplementary Figure S3</xref> for HPLC and mass spectrometry chromatograms/spectra of the synthesized peptides R954 and NOTA-&#946;Ala-R954). Abbreviations for amino acids follow the recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature. Other abbreviations are described as follows: Orn, <sc>l</sc>-ornithine; Oic, <sc>l</sc>-(2S,3aS,7aS)-octahydro-1H-indol-2-carboxylic acid; (&#945;Me)Phe, &#945;-methyl-<sc>l</sc>-phenylalanine; &#946;-Nal, 3-(2-naphthyl)-<sc>l</sc>-alanine.</p></sec><sec id="sec2dot10-pharmaceutics-17-01215"><title>2.10. Labeling of NOTA&#8211;Peptides with <sup>64</sup>Copper (<sup>64</sup>Cu) or Natural Cu (<sup>Nat</sup>Cu)</title><p>The NOTA&#8211;peptide conjugate was next labeled with <sup>64</sup>Cu under previously optimized conditions [<xref rid="B39-pharmaceutics-17-01215" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-17-01215" ref-type="bibr">40</xref>]. Briefly, the NOTA-&#946;Ala-R954 (3&#8211;5 nmol) was incubated with [<sup>64</sup>Cu]Cu(OAc)<sub>2</sub> (240&#8211;450 MBq) in 0.1 M ammonium acetate buffer pH 5.5 in a total volume of 300&#8211;400 &#956;L. The resulting solution was incubated at room temperature for 15&#8211;20 min. The radio chemical yield (RCY &gt; 99%) was determined by radio-TLC on C18 plates with 0.1 M sodium citrate buffer (pH 5.5) as the mobile phase; conditions were optimized to achieve quantitative labeling without HPLC or C18 purification. The amount of radioactivity of labeled peptides was measured using a Capintec radioisotope dose calibrator (Capintec, Inc., Florham Park, NJ, USA). The resulting <sup>64</sup>Cu-peptides were reconstituted in phosphate-buffered saline (PBS, pH 7.4) for in vitro studies or in isotonic saline for in vivo studies.</p><p>For labeling with <sup>Nat</sup>Cu, 2 mg of the NOTA-conjugated peptide was resuspended in 200 &#181;L of a 0.1 M ammonium acetate in water/ACN (1:1). Three equivalents of Cu(OAc)<sub>2</sub> in water (0.03 M) were added, and the mixture was incubated at room temperature for 30 min. ULPC-MS analysis confirmed the incorporation of copper in the NOTA moiety of the peptide (+61, addition of copper minus two hydrogen). The reaction mixture was then lyophilised and purified using solid-phase extraction (SPE) columns to remove excess copper. The SPE procedure involved conditioning the columns with acetonitrile (ACN) twice, equilibration with water containing 0.1% TFA, applying the peptide dissolved in 0.1% TFA, washing with water containing 0.1% TFA, and eluting with 75% ACN in water containing 0.1% TFA. The collected eluate was lyophilized and stored at &#8722;20 &#176;C until further use.</p></sec><sec id="sec2dot11-pharmaceutics-17-01215"><title>2.11. Generation of Stable Human Kinin B1R-HEK293 Cell Line</title><p>The B1R minigene (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000710">NM_000710</ext-link>) was synthesized (Integrated DNA Technologies, Coralville, IA, USA) and cloned into the lentiviral vector pCDH-CMV-MCS-EF1-puro (System Biosciences, Palo Alto, CA, USA) using BamHI and NotI restriction enzymes (New England Biolab, Ipswich, MA, USA). Lentiviruses were produced by co-transfecting HEK293T cells with the lentiviral vector containing the human B1R gene (hB1R) (pCDH-CMV-B1R-MCS-EF1-puro), the psPAX2 packaging plasmid (a gift from Didier Trono, Addgene plasmid #12260), and the pMD2.G plasmid expressing VSV-G (a gift from Didier Trono, Addgene plasmid #12259) using PEI (Sigma-Aldrich) as the transfection reagent. Lentiviruses were harvested 48 h post-transfection and used to infect QBI HEK293A cells (ATCC). Transduced cells were selected using 1 &#181;g/mL of puromycin (Thermo Fisher Scientific). B1R mRNA expression in the transduced cells was confirmed by radioligand binding studies using [<sup>3</sup>H]-LysdesArg<sup>9</sup>BK, (ART2475; 90&#8211;120 Ci/mmol; American Radiolabeled Chemicals Inc., St. Louis, MO, USA), yielding a Kd value of 1.3 nM and a Bmax of 181,000 sites/cell (corresponding to about 1.24 pmol/mg protein). The generation of stably transfected human kinin B2R-HEK293 cell lines used in this study has been described in detail elsewhere [<xref rid="B37-pharmaceutics-17-01215" ref-type="bibr">37</xref>].</p></sec><sec id="sec2dot12-pharmaceutics-17-01215"><title>2.12. Ligand Competition Binding Assays</title><p>Radiolabeled ligand competition binding assays were performed on HEK293 cells stably expressing hB1R or hB2R, as previously described [<xref rid="B37-pharmaceutics-17-01215" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-17-01215" ref-type="bibr">38</xref>]. Cells were cultured in 24-well plates and incubated with 4 nM [<sup>3</sup>H]Lys[Leu<sup>8</sup>]desArg<sup>9</sup>BK (for B1R studies) (ART1583; 90&#8211;120 Ci/mmol; American Radiolabeled Chemicals) or 1 nM [<sup>3</sup>H]BK (for B2R studies) (NET706; 109 Ci/mmol; Perkin-Elmer, Woodbridge, ON, Canada) in serum-free DMEM for 1&#8211;2 h in the absence or presence of increasing concentrations of competitors (10<sup>&#8722;11</sup>&#8211;10<sup>&#8722;5</sup>M). Radioactivity in the samples was measured using a &#946;-scintillation counter (Tri-Carb 2800; Perkin-Elmer). Binding affinities were expressed as IC<sub>50</sub> values, calculated using GraphPad Prism version 8.2.1 software (GraphPad Software, San Diego, CA, USA).</p></sec><sec id="sec2dot13-pharmaceutics-17-01215"><title>2.13. Generation of NFAT-eGFP Reporter Cells</title><p>The pLenti-6V5-NFAT-eGFP vector was generated from the pSIRV-NFAT-eGFP vector (a gift from Peter Steinberger, Addgene plasmid #118031). Briefly, NFAT-eGFP gene was PCR amplified using the following primers: 5&#8242;-TTTTATCGATTCCTCTAGACTGCCGGATC-3&#8242; and 5&#8242;-AAAACCGGTCGATCGACCACTGTGC-3&#8242;). The amplified gene was then ligated into the ClaI and AgeI restriction sites of the pLenti-6V5 vector. Lentiviruses were produced using the pLenti-6V5-NFAT-eGFP vector in HEK293T cells and used to transduce a hB1R-expressing CHO cell line, followed by selection with 10 &#181;g/mL blasticidin. The stable cell population was treated with 1 &#956;M of LysdesArg<sup>9</sup>BK (LDBK; reference agonist of hB1R) [<xref rid="B41-pharmaceutics-17-01215" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-17-01215" ref-type="bibr">42</xref>] for 24 h and then sorted for high fluorescence expression using a Sony SH800S cell sorter (Sony Biotechnology, San Jose, CA, USA). Clones were grown in 4000 nanowells/well in 24-well plates and re-plated into 96-well plates after initial expansion via the ALS CellCelector&#8482; (Sartorius Corporation, Bohemia, NY, USA). After clonal expansion, individual cell lines were evaluated based on their ratio of stimulated fluorescence to basal expression to determine maximum sensitivity. The most effective clone was retained as the hB1R reporter cell line.</p></sec><sec id="sec2dot14-pharmaceutics-17-01215"><title>2.14. NFAT-eGFP-Based Reporter Assays</title><p>Fluorescence assays performed on CHO-hB1R-NFAT-eGFP cells. Target cells were plated at 10,000 cells/well in a 96-well microplate (opaque black wells with clear flat bottom, Thermo Scientific, Rockford, IL, USA) using RPMI 1640 medium with 10% fetal bovine serum (FBS). After 24 h, the medium was replaced by RPMI without FBS and phenol red. Cells were then stimulated with the B1R agonist LDBK at concentrations ranging from 1 pM to 10 &#956;M at 37 &#176;C/5% CO<sub>2</sub> for 16 h, in the presence or absence of 500 nM antagonists (preincubated for 10 min prior to agonist addition). Prolonged stimulation times (24 h and 48 h) did not result in increased EGFP signal levels. Fluorescence was measured using a TECAN M1000 (Tecan Group Ltd., M&#228;nnedorf, Switzerland) multimode microplate reader with excitation at 488 nm and emission at 507 nm. Each data point represents a ratio of two values, divided by the average fluorescence of six control wells. The potencies of the agonists LDBK (EC<sub>50</sub> value: 2.1 nM) and desArg<sup>9</sup>-BK (DBK: EC<sub>50</sub> value: 297 nM), consistent with the expected pharmacological profiles on hB1R [<xref rid="B42-pharmaceutics-17-01215" ref-type="bibr">42</xref>], were calculated by curve-fitting using GraphPad Prism 8.2.1 (GraphPad Software) (<xref rid="app1-pharmaceutics-17-01215" ref-type="app">Supplementary Table S2</xref>). Antagonist affinity (Kb) was estimated from functional inhibition curves using the Gaddum (Schild) equation assuming competitive antagonism at human B1R: Kb = [B]/(dose-ratio&#8211;1), where [B] is the antagonist concentration, and the dose ratio is EC<sub>50</sub> + Compound/EC<sub>50</sub>.</p></sec><sec id="sec2dot15-pharmaceutics-17-01215"><title>2.15. Human Vein Contractility Assays</title><p>The potency (apparent affinity) of non-radioactive NOTA-&#946;Ala-R954 peptide conjugates at native inducible B1R was assessed using human tissue bioassays with isolated umbilical veins, as previously described [<xref rid="B41-pharmaceutics-17-01215" ref-type="bibr">41</xref>,<xref rid="B43-pharmaceutics-17-01215" ref-type="bibr">43</xref>]. Collection of umbilical cords for these bioassays was approved by the CHUS Human Research Ethics Committee (protocol #97-14; 21 March 1997), and maternal consent was obtained in all cases. Antagonist affinity was expressed in terms of IC<sub>50</sub>, which represents the molar concentration of an antagonist that reduces the response to a submaximal concentration of the DBK agonist by 50%.</p></sec><sec id="sec2dot16-pharmaceutics-17-01215"><title>2.16. Ex Vivo/In Vivo Blood Stability Assays</title><p>Experiments were performed according to previously published procedures [<xref rid="B39-pharmaceutics-17-01215" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-17-01215" ref-type="bibr">40</xref>]. Briefly, aliquots (20 &#181;L) of radiolabeled R954 peptide conjugate (110&#8211;185 MBq; 3&#8211;5 mCi) were mixed with 250 &#181;L of undiluted plasma collected from healthy Balb/C mice or human male volunteers and incubated in a 37 &#176;C water bath for 24 h. After incubation, the samples were treated with acetonitrile at a 1:1 ratio, followed by centrifugation at 13,000&#215; <italic toggle="yes">g</italic> for 15 min to precipitate and remove plasma proteins. A 100 &#181;L aliquot was taken from the supernatant and analyzed using a Waters<sup>&#174;</sup> ACQUITY UPLC<sup>&#174;</sup> H-Class Bio System equipped with an ELSD detector (Waters Corporation) and a BioScan Flow Count radiodetector (BioScan Inc., Washington DC, USA).</p><p>In vivo stability assays were carried out following bolus intravenous (IV) injection of radiolabeled R954 peptide conjugate (54 MBq; 1.5 mCi; 200 &#956;L) into the tail vein of air/isoflurane-anesthetized normal Balb/C mice. Terminal blood and urine samples were collected 90 min post-injection from anesthetized animals via carotid puncture (blood) and bladder puncture (urine). Blood samples were centrifuged at 2000&#215; <italic toggle="yes">g</italic> for 15 min at 4 &#176;C, and the resulting plasma supernatants were processed as described above for UPLC analyses. The integrity of the radiolabeled peptide was assessed by comparing the retention times of plasma and urine samples to those of the control, unprocessed radiolabeled peptide.</p></sec><sec id="sec2dot17-pharmaceutics-17-01215"><title>2.17. Cellular Uptake and Nuclear Localization</title><p>Cellular uptake profile of <sup>64</sup>Cu-labeled R954 peptide conjugate was evaluated in PCa cells as described [<xref rid="B39-pharmaceutics-17-01215" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-17-01215" ref-type="bibr">40</xref>], with some modifications. Cells were seeded into 6-well plates (2.5 &#215; 10<sup>5</sup> cells/well) 48 h before the beginning of experiments. Cells were then incubated in fresh media with <sup>64</sup>Cu-labeled R954 (10 kBq; ~500 nM final) at 37 &#176;C for 15 min, 4 h, or 24 h. For determination of specific internalization, one set of wells was preincubated with unlabeled free R954 (1 &#181;M) at 37 &#176;C for 10 min to block B1R prior to incubation with <sup>64</sup>Cu-labeled R954. At each time point, radioactive media was collected, and wells were successively washed, once with Hank&#8217;s balanced salt solution (HBSS), treated with 50 mM CH<sub>3</sub>COOH/250 mM NaCl (pH 2.5) for 3 min (to remove surface-bound fraction), and twice with PBS, pH 7.4. Thereafter, cells were gently harvested with Gibco&#8217;s StemPro Accutase (Life Technologies Corp, Grand Island, NY, USA). In some experiments, PCa-derived nuclei were also isolated after the indicated time point using the procedures described in the following section. <sup>64</sup>Cu activity in the media, intact cells, and isolated nuclei was then measured with a gamma counter (Cobra II auto-gamma counter, Packard, Minneapolis, MN, USA). The percentage of radioactivity in the nucleus was determined as the ratio of gamma counts in the pure nuclei over gamma counts associated with whole cells. Precise cell/nucleus counts (with Trypan blue staining) were determined on mirror plates following cell detachment or nuclei isolation procedure.</p></sec><sec id="sec2dot18-pharmaceutics-17-01215"><title>2.18. Cell Fractionation and Nuclei Isolation</title><p>PCa cells were grown on 100 mm dishes at confluency. Following treatment with <sup>64</sup>Cu-labeled R954, adherent cells were washed once in Hank&#8217;s balanced salt solution (HBSS) then subjected to an acid wash (50 mM acetic acid/250mM NaCl at room temperature) for 3 min to remove any residual membrane-bound radiolabeled peptides. Cells were next washed twice with PBS, detached using StemPro Accutase<sup>&#174;</sup> solution (Life Technologies), washed once more with PBS, and then counted. Cell nuclei were isolated according to Wang et al. [<xref rid="B44-pharmaceutics-17-01215" ref-type="bibr">44</xref>] with some modifications. Briefly, cell pellets were resuspended in hypotonic lysis buffer solution (10 mM PIPES pH 6.8, containing 100 mM NaCl, 2 mM MgCl<sub>2</sub>, 300 mM sucrose, and 0.5% Triton X-100) and allowed to rest on ice for 3 min. Samples were then diluted ten times with hypotonic buffer without Triton X-100, centrifuged at 700&#215; <italic toggle="yes">g</italic> for 5 min. The resulting supernatant (cytoplasmic fraction) was then collected while the pellet (nuclear fraction) was resuspended in detergent-free hypotonic buffer. Total proteins in cytoplasmic and nuclear extracts were measured using BCA&#8482; (bicinchoninic acid) protein assay kit (Thermo Scientific). Purity of nuclear fractions were assessed by light microscopy after trypan blue staining and by Western blotting with a set of antibodies against specific organelle markers: lamin A/C and nuclear pore complex (nucleus), clathrin and Na<sup>+</sup>/K<sup>+</sup> ATPase (cell membrane), calnexin (endoplasmic reticulum), LAMP-2 (lysosome), cytochrome C (mitochondria), and tubulin (cytosol) (see text below).</p></sec><sec id="sec2dot19-pharmaceutics-17-01215"><title>2.19. Western Blotting</title><p>Western blotting was performed on 25&#8211;50 &#181;g of heat-denatured protein extracts, prepared by homogenization in conventional RIPA buffer containing a protease inhibitor cocktail (Sigma-Aldrich), migrated through a 9&#8211;12% acrylamide gradient SDS-PAGE Tris-Glycine gel (Invitrogen), and electroblotted onto PVDF membranes. Blots were blocked using 5% non-fat dry milk and probed using appropriate primary antibodies in blocking buffer overnight at 4 &#176;C. Proteins were visualized using a goat anti-rabbit (1:10,000) or anti-mouse (1:20,000) secondary antibody conjugated to enzyme horseradish peroxidase (HRP) and a western lightning chemiluminescence detection kit, as per manufacturer&#8217;s instructions (PerkinElmer), and revealed by use of X-Omat film (Eastman Kodak Company, Rochester, NY, USA).</p></sec><sec id="sec2dot20-pharmaceutics-17-01215"><title>2.20. Intracellular Copper Measurement by Inductively Coupled Plasma Mass Spectrometry (ICP-MS)</title><p>PCa cells were seeded in 10 cm plates and after reaching ~90% of confluency they were exposed or not to non-radioactive <sup>Nat</sup>Cu/NOTA-&#946;Ala-R954 for 24 h at 37 &#176;C in RPMI 1640 media with 1% FBS. Cells were washed once in HBSS then subjected to an acid wash as above mentioned. Thereafter, cells were washed twice with PBS, harvested using StemPro Accutase<sup>&#174;</sup> solution (Life Technologies), centrifuged twice in PBS, and then counted. Cell nuclei were isolated as described above (<xref rid="sec2dot18-pharmaceutics-17-01215" ref-type="sec">Section 2.18</xref>). Cell pellets and nuclei were resuspended and digested overnight at 37 &#176;C in a 50:50 mixture of concentrated HNO<sub>3</sub>/30% H<sub>2</sub>O<sub>2</sub>. Dissolved Cu was measured with inductively coupled plasma mass spectrometry (ICP-MS; Perkin-Elmer Elan DRC II). Samples were diluted with nanopure H<sub>2</sub>O to a final concentration of 2% nitric acid/0.4% H<sub>2</sub>O<sub>2</sub> solution (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) before Cu measurements. Cu calibration standards (from 0.1 to 50 ppb) were prepared in the same 2% nitric acid/0.4% H<sub>2</sub>O<sub>2</sub> solution.</p></sec><sec id="sec2dot21-pharmaceutics-17-01215"><title>2.21. Clonogenic Assays</title><p>PCa cells were seeded in 6-well plates (at ~400 cells/well) in RPMI medium supplemented with 10% FBS and treated 24 h later with varying doses of either the <sup>64</sup>Cu-labeled R954 conjugate or its <sup>Nat</sup>Cu counterpart. The plates were incubated at 37 &#176;C for approximately 10 to 14 days, before staining and counting [<xref rid="B45-pharmaceutics-17-01215" ref-type="bibr">45</xref>]. To prevent possible bystander irradiating effects from occurring, cells were seeded in one well on two opposite sides of 6-well dishes.</p></sec><sec id="sec2dot22-pharmaceutics-17-01215"><title>2.22. Subcutaneous Xenograft Models of Human PCa</title><p>Male Nu/Nu nude mice (Crl:NU-Foxn1nu: 4&#8211;6 weeks old, Charles River Laboratories, Inc., Wilmington, MA, USA) were subcutaneously (s.c.) inoculated into one or both lower flanks with PCa cells. LNCap cells (10 x 10<sup>6</sup>) and PC3 cells (2.5 &#215; 10<sup>6</sup>) were suspended in 0.2 mL of a 1:1 (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) mixture of antibiotic-free DMEM medium and Matrigel (#356234, Sigma-Aldrich) for injection. Within 10&#8211;21 days post-inoculation, solid palpable prostate tumors had developed, and the animals were used for biodistribution, PET imaging, and radiotherapy studies. All animal experimentation was approved by the Animal Care Committee (CPA) of the Faculty of Medicine and Health Sciences (FMSS), Universit&#233; de Sherbrooke (protocols #392-15BR, 14 July 2015; #2019-2371, 5 March 2020) and conducted in accordance with the guidelines of Canadian Council on Animal Care.</p></sec><sec id="sec2dot23-pharmaceutics-17-01215"><title>2.23. Biodistribution Studies and Micro-PET Imaging</title><p>To perform ex vivo biodistribution studies, radiolabeled peptides (5&#8211;10 MBq; 100 &#956;L) were administered to isoflurane-anaesthetized normal male Balb/c mice through caudal vein injection. Organs were collected 1 h and 4 h post-injections from CO<sub>2</sub> inhalation-euthanized animals and were washed, weighted, and radioactivity measured in a gamma counter (Cobra II auto-gamma counter, Packard). The percentage of injected dose per gram of tissue (%ID/g) was then calculated, accounting for decay correction, using external <sup>64</sup>Cu standards. Biodistribution of the radiolabeled peptides was also performed in PCa tumor-bearing nude mice using micro-PET imaging performed on a 7.5 cm axial and 10 cm transaxial field of view LabPET8 small-animal scanner (Gamma Medica-IDEAS Inc., Northridge, CA, USA) in combination with X-ray computer tomography (CT) (MILabs U-CT system, Utrecht, The Netherlands) [<xref rid="B46-pharmaceutics-17-01215" ref-type="bibr">46</xref>]. For this, radiolabeled peptides (6&#8211;9 MBq in 200 &#956;L) were delivered by tail-vein injection to isoflurane-anaesthetized mice. PET scans composed of 30 min static acquisition were acquired at 1 h and 20 h after injection. Using the PMOD software (version 3.8, PMOD Technologies Ltd., Zurich, Switzerland), the PET image of each animal was co-registered with the corresponding CT image by a rigid matching transformation. PET images were converted to a percentage of injected dose per gram (%ID/g) using a calibration phantom loaded with known activity concentration [<xref rid="B47-pharmaceutics-17-01215" ref-type="bibr">47</xref>]. To quantify the tumor uptake of the radiotracer, a volume of interest (VOI) was drawn around the center of the tumor. The uptake was determined as the means of the VOI voxels having intensity in the upper quartile.</p></sec><sec id="sec2dot24-pharmaceutics-17-01215"><title>2.24. Peptide Receptor Radionuclide Therapy (PRRT)</title><p>Therapeutic efficacies of agents were investigated in PC3 xenograft-bearing mice. Once tumors reached a size of 50&#8211;200 mm<sup>3</sup>, mice were randomly assigned to three groups and treated via tail-vein injection with either a single equivalent dose of <sup>64</sup>Cu/NOTA-&#946;Ala-R954 (50 &#181;g/kg; 65 MBq or 1.75 mCi), its non-radioactive counterpart <sup>Nat</sup>Cu/NOTA-&#946;Ala-R954 (50 &#181;g/kg), or an equal volume of control vehicle (100 &#181;L isotonic saline), under mild isoflurane anesthesia. Although no dosimetric analysis was performed, the selected radiation dose was guided by previously published studies and was within the established range commonly used for <sup>64</sup>Cu-based radiotherapy applications [<xref rid="B48-pharmaceutics-17-01215" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-17-01215" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceutics-17-01215" ref-type="bibr">50</xref>,<xref rid="B51-pharmaceutics-17-01215" ref-type="bibr">51</xref>]. Tumor growth was monitored with a digital vernier caliper using the following formula: length &#215; width<sup>2</sup>. The weight of the mice was monitored throughout the study. The first day of drug administration was designated as day 0. Tumor growth was normalized by calculating the ratio of the tumor volume at each time point to the initial tumor volume measured prior to treatment. The weight of the mice was monitored throughout the study. At the end of experiments, all animals were euthanized by CO<sub>2</sub> asphyxiation and tumors were then totally excised, photographed, and FFPE blocks of tumor tissues prepared for IHC biomarker analyses.</p></sec><sec id="sec2dot25-pharmaceutics-17-01215"><title>2.25. IHC Staining of Resected PCa Xenografts</title><p>Retrieved subcutaneous tumors (5 &#956;m thick sections) were evaluated by H&amp;E and semiquantitative IHC staining of B1R, Ki67 (proliferation), cleaved caspase 3 (apoptosis), CD34 (angiogenesis), and LYVE-1 (lymphangiogenesis). An isotype-matched rabbit-/mouse-IgG (Dako, Hamburg, Germany), instead of the primary antibody, served as negative controls (see <xref rid="app1-pharmaceutics-17-01215" ref-type="app">Supplementary Figure S2</xref>). Multiple fields of view were imaged for experimental groups to ensure adequate representation of the whole tumors. Whole slides were digitized using Hamamatsu NanoZoomer scanning system (Hamamatsu Corporation) and quantitative image analysis carried out using Image-Pro Plus (version 5.1; Media Cybernetics, Rockville, MD, USA) or Nanozoomer Digital Pathology (NDP) view 2 imaging software (version 2.6.13; Hamamatsu Corporation). For the analysis of each IHC-stained tissue section, an average of 3&#8211;5 fields per tumor (3&#8211;4 tumors per group), excluding necrotic zones, were randomly sampled (under 10 to 40&#215; magnification). For Ki67, only nuclear immunoreactivity was considered specific, as recommended in the literature [<xref rid="B52-pharmaceutics-17-01215" ref-type="bibr">52</xref>]. Positive Ki67 staining was determined by the nucleus count (Ki-67+ cells/total cells) in sampled fields. CD34 or LYVE-1-positive microvessel number were counted and reported over the total area (in mm<sup>2</sup>) used for counting (calculated using Nanozoomer Digital Pathology software version 2.6.13). Quantification of active caspase-3 and B1R-positive immunostaining was achieved by dividing the number of positive pixels by the total pixel count in each selected field. For B1R, calculated values from treated specimens were normalized to those of untreated control tumors. Selection and discrimination between positive and negative pixels were performed using the color segmentation tool of Image-Pro plus software (version 5.1; Media Cybernetics).</p></sec><sec id="sec2dot26-pharmaceutics-17-01215"><title>2.26. Statistical Analysis</title><p>Data are expressed as the mean &#177; sem. Where appropriate, the data were analyzed by either one-way ANOVA followed by Dunnett&#8217;s test, Tukey&#8217;s multiple comparison test, or unpaired Student&#8217;s <italic toggle="yes">t</italic>-test (GraphPad Prism v10.2). <italic toggle="yes">p</italic> values &lt; 0.05 were considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-01215"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-17-01215"><title>3.1. Expression of B1R in Human PCa Cell Lines and Tumors</title><p>RT-qPCR analysis demonstrated comparable levels of B1R expression across all tested human PCa cell lines (LNCaP, PC3, 22RV1, DU145; <xref rid="pharmaceutics-17-01215-f001" ref-type="fig">Figure 1</xref>A). Among them, LNCaP and PC3 exhibited cell surface B1R expression, as evidenced by FACS analysis (<xref rid="app1-pharmaceutics-17-01215" ref-type="app">Supplementary Figure S4</xref>). Additionally, B1R gene expression analysis in four human PCa cell line-derived xenografts (CDXs) implanted in Nu/Nu mice revealed moderate variability, with log2 values ranging from 6.6 to 9.2 across the xenografts (<xref rid="pharmaceutics-17-01215-f001" ref-type="fig">Figure 1</xref>B). In a series of PCa tumors and paired adjacent non-cancerous tissues (<italic toggle="yes">n</italic> = 14), B1R mRNA expression levels were significantly overexpressed, with increases of up to 40-fold (<italic toggle="yes">p</italic>-value: &lt; 0.05, <xref rid="pharmaceutics-17-01215-f001" ref-type="fig">Figure 1</xref>C). Semi-quantitative assessment of B1R protein levels using PCa tissues microarrays (<xref rid="pharmaceutics-17-01215-f001" ref-type="fig">Figure 1</xref>D) showed significantly higher expression in tumors compared to normal prostate glands, with protein levels positively correlating with Gleason scores (Spearman r: 0.385, <italic toggle="yes">p</italic>-value: &lt; 0.0001). Notably, B1R positivity remained strong in one metastatic PCa case (ganglia) examined. These findings were further supported by analyses of two independent datasets retrieved from cBioPortal (MSKCC and TCGA Firehose Legacy), which also revealed positive correlations between B1R mRNA expression and tumor Gleason scores (<xref rid="pharmaceutics-17-01215-f001" ref-type="fig">Figure 1</xref>E). Furthermore, Kaplan&#8211;Meier survival analyses using the MSKCC and TCGA databases indicate that elevated B1R expression is associated with poor survival outcomes in PCa patients (<xref rid="pharmaceutics-17-01215-f001" ref-type="fig">Figure 1</xref>F). Altogether, these findings indicate that B1R overexpression contributes to PCa progression, underscoring its potential as both a biomarker and a therapeutic target, positioning it as a promising candidate for theranostics.</p></sec><sec id="sec3dot2-pharmaceutics-17-01215"><title>3.2. Synthesis, <sup>64</sup>Cu Radiolabeling, and Stability of a New NOTA-Conjugated Analog of R954 for Theranostic Applications</title><p>The theranostic peptide sequence based on the B1R antagonist R954, and previously reported in our earlier preliminary study [<xref rid="B53-pharmaceutics-17-01215" ref-type="bibr">53</xref>], is depicted in <xref rid="pharmaceutics-17-01215-f002" ref-type="fig">Figure 2</xref>A. The synthesis of NOTA-&#946;Ala-R954 and its parent peptide R954 was straightforward, achieving purities exceeding 98%, as confirmed by HPLC and mass spectrometry (NOTA-&#946;Ala-R954: mw = 1508.8; R954: mw = 1194.5). Radiolabeling of NOTA-&#946;Ala-R954 with <sup>64</sup>Cu produced a peptide with an apparent molar activity of 104.7 &#177; 7.6 MBq/nmol (equivalent to 69.4 MBq/&#181;g peptide) and a radiochemical purity greater than 98% (<xref rid="pharmaceutics-17-01215-f002" ref-type="fig">Figure 2</xref>B). Stability studies show no evidence of peptide radiolysis observed over a 24 h period, as confirmed by radio-UPLC and radio-TLC analyses (<xref rid="pharmaceutics-17-01215-f002" ref-type="fig">Figure 2</xref>C and 2D, respectively). Ex vivo blood stability assessments reveal that the <sup>64</sup>Cu/NOTA-&#946;Ala-R954 exhibited exceptional stability, with no signs of degradation or transmetallation in undiluted mouse and human plasma after a 20 h incubation period (<xref rid="pharmaceutics-17-01215-f002" ref-type="fig">Figure 2</xref>E). Furthermore, in vivo studies confirmed the presence of predominantly intact radiolabeled peptides in mouse blood circulation and urine 90 min after intravenous injection (<xref rid="pharmaceutics-17-01215-f002" ref-type="fig">Figure 2</xref>F).</p></sec><sec id="sec3dot3-pharmaceutics-17-01215"><title>3.3. Competitive Binding Affinity, Selectivity, and Potency Assays at Recombinant and Native hB1R and hB2R</title><p>The results of the pharmacological evaluation of <sup>Nat</sup>Cu/NOTA-&#946;Ala-R954, conducted through multiple in vitro assays, are summarized in <xref rid="pharmaceutics-17-01215-t001" ref-type="table">Table 1</xref>. Binding experiments conducted with HEK293 cells stably expressing hB1R or hB2R demonstrate that the peptide conjugate, whether labeled with Cu or not, retained strong nanomolar affinity for hB1R, albeit slightly lower than its parent peptide R954 (see IC<sub>50</sub> values). As expected from the properties of the parent molecule, no detectable binding interaction was observed with hB2R (IC<sub>50</sub> values &gt; 10 &#181;M), confirming its high selectivity. At the cellular level, the peptide conjugates effectively antagonized NFAT luciferase-eGFP reporter activity stimulated by the B1R agonist LDBK, exhibiting low Kb values ranging from 0.4 to 2.2 nM, comparable to that of the unconjugated R954. At the tissue level, ex vivo functional studies using the contraction of isolated human vein vessels show that NOTA covalent conjugation on R954 did not compromise its antagonist potency against native hB1R, while consistently remaining inactive on hB2R.</p></sec><sec id="sec3dot4-pharmaceutics-17-01215"><title>3.4. In Vitro Cellular Uptake, Nuclear Distribution, and Anticancer Activity of <sup>64</sup>Cu/NOTA-&#946;Ala-R954 in PCa Cells</title><p>Cellular uptake is a prerequisite for the effective use of <sup>64</sup>Cu-labeled agents in biomedical fields, such as PET imaging and PRRT. The data presented in <xref rid="pharmaceutics-17-01215-f003" ref-type="fig">Figure 3</xref> provide insights into the cellular uptake dynamics, nuclear localization, and anticancer activity of <sup>64</sup>Cu/NOTA-&#946;Ala-R954 in PCa cells. Radiometric analysis demonstrate a time-dependent uptake of <sup>64</sup>Cu/NOTA-&#946;Ala-R954, reaching 33% of the injected dose (ID) at 24 h in PC3 cells. Pre-treatment with an excess of B1R antagonist R954 significantly reduced this uptake, confirming the receptor specificity of the process (<xref rid="pharmaceutics-17-01215-f003" ref-type="fig">Figure 3</xref>A). These findings were further corroborated through inductively coupled plasma mass spectrometry (ICP-MS) analysis, utilizing the <sup>Nat</sup>Cu-labeled form of the peptide (<xref rid="pharmaceutics-17-01215-f003" ref-type="fig">Figure 3</xref>B).</p><p>The delivery of <sup>64</sup>Cu-labeled peptides to the cell nuclei is known to boost their therapeutic efficacy by emitting Auger electrons, which cause localized DNA damage [<xref rid="B30-pharmaceutics-17-01215" ref-type="bibr">30</xref>]. To investigate the nuclear distribution of the <sup>64</sup>Cu/NOTA-&#946;Ala-R954, PC3 cells were incubated with the compound for 24 h, followed by subcellular fractionation. The high purity of the nuclear fractions was validated through optical microscopy, which confirmed the absence of intact cells, and by Western blot analysis (<xref rid="pharmaceutics-17-01215-f003" ref-type="fig">Figure 3</xref>C). The Western blot results confirm the presence of established nuclear protein markers lamin A/C and nucleoporin, while markers of other subcellular compartments, including LAMP-2 (lysosomes), cytochrome C (mitochondria), clathrin (endosomes), Na<sup>+</sup>/K<sup>+</sup>ATPase (plasma membrane), and tubulin (cytoskeleton), were absent. The detection of calnexin was consistent with its expected localization, as the rough endoplasmic reticulum is contiguous with the nuclear envelope. Quantitative analysis reveals that 5% of the ID of <sup>64</sup>Cu-labeled peptide&#8212;equating to approximately 16% of total intracellular uptake&#8212;was localized within or had reached the nuclear compartment 24 h post-incubation (<xref rid="pharmaceutics-17-01215-f003" ref-type="fig">Figure 3</xref>C).</p><p>The dose-dependent cytotoxic activity of the <sup>64</sup>Cu-labeled B1R peptide, compared to the control non-radioactive B1R peptide similarly labeled with <sup>Nat</sup>Cu, was evaluated using clonogenic assays (<xref rid="pharmaceutics-17-01215-f003" ref-type="fig">Figure 3</xref>D). Results show that <sup>64</sup>Cu/NOTA-&#946;Ala-R954 effectively suppressed clonogenic growth in both LNCaP and PC3 cell lines in a dose-dependent manner, whereas the nonradioactive counterpart, <sup>Nat</sup>Cu/NOTA-&#946;Ala-R954, even at a much higher concentration (10 &#181;M), had no effect on their clonogenic potential.</p></sec><sec id="sec3dot5-pharmaceutics-17-01215"><title>3.5. In Vivo Biodistribution and Micro-PET Imaging of <sup>64</sup>Cu/NOTA-&#946;Ala-R954</title><p>The results of the in vivo tissue biodistribution of IV-administered <sup>64</sup>Cu/NOTA-&#946;Ala-R954 in normal male BALB/c mice, along with the PET imaging findings in male nude mice bearing subcutaneous PCa tumors, are summarized in <xref rid="pharmaceutics-17-01215-f004" ref-type="fig">Figure 4</xref>. The results demonstrate rapid clearance of the radioactive peptide from the bloodstream, as observed at 1 h and 4 h post-injection. Significantly higher levels of radioactivity were detected in the kidneys compared to other organs, gradually decreasing over time from 24% to 10% of the injected dose per gram of tissue (ID/g) (<xref rid="pharmaceutics-17-01215-f004" ref-type="fig">Figure 4</xref>A). These findings highlight the peptide&#8217;s preferential accumulation and excretion through renal pathways, consistent with previously reported observations for the parental peptide R954 [<xref rid="B23-pharmaceutics-17-01215" ref-type="bibr">23</xref>]. Moreover, PET images acquired 1 h after injection of <sup>64</sup>Cu/NOTA-&#946;Ala-R954 clearly visualized the PC3 tumors located in the flanks (<xref rid="pharmaceutics-17-01215-f004" ref-type="fig">Figure 4</xref>B, left panel). The accumulation of the radioconjugate (7 MBq; ~4 &#181;g/kg) in PC3 tumors, as shown by PET imaging, but not in the muscles or kidneys, could be blocked by an excess of unlabeled R954 (1 mg/kg). This demonstrates the peptide&#8217;s specificity for B1R-expressing tumors, as confirmed by positive IHC staining of resected tumors at the specified time post-inoculation (<xref rid="pharmaceutics-17-01215-f004" ref-type="fig">Figure 4</xref>B, right panel). At 1 and 20 h post-injection, the tumor-to-blood, tumor-to-muscle, and tumor-to-kidney ratios for <sup>64</sup>Cu/NOTA-&#946;Ala-R954 significantly increased, suggesting a preferential retention of the radiotracer in tumor tissues over time compared to other compartments (<xref rid="pharmaceutics-17-01215-f004" ref-type="fig">Figure 4</xref>C).</p></sec><sec id="sec3dot6-pharmaceutics-17-01215"><title>3.6. Effects of PRRT with <sup>64</sup>Cu/NOTA-&#946;Ala-R954 on PCa Growth</title><p>The comparison of the anticancer efficacy of an equivalent single-dose IV administration of <sup>64</sup>Cu/NOTA-&#946;Ala-R954 (50 &#181;g/kg; 65 MBq) and <sup>Nat</sup>Cu/NOTA-&#946;Ala-R954 (50 &#181;g/kg) in nude mice bearing s.c. PC3 xenografts is presented in <xref rid="pharmaceutics-17-01215-f005" ref-type="fig">Figure 5</xref>. In contrast to the non-radioactive <sup>Nat</sup>Cu-labeled peptide, the <sup>64</sup>Cu/NOTA-&#946;Ala-R954 conjugate significantly reduced tumor growth (<xref rid="pharmaceutics-17-01215-f005" ref-type="fig">Figure 5</xref>A). Notably, the PRRT treatment did not induce any observable toxicity, as indicated by the absence of changes in body weight throughout the study (<xref rid="pharmaceutics-17-01215-f005" ref-type="fig">Figure 5</xref>B). This anti-tumor activity was attributed to mechanisms involving cancer cell apoptosis, as indicated by increased expression of active caspase-3, and reduced proliferation, evidenced by the downregulation of Ki67 biomarkers (<xref rid="pharmaceutics-17-01215-f005" ref-type="fig">Figure 5</xref>C). Angiogenesis and lymphangiogenesis are key features of PCa progression and metastasis [<xref rid="B54-pharmaceutics-17-01215" ref-type="bibr">54</xref>]. Therefore, the expression of CD34 and LYVE-1, markers for vascular and lymphatic vessels, respectively, was also assessed in resected prostate tumors from mice treated with or without <sup>64</sup>Cu/NOTA-&#946;Ala-R954 using IHC (<xref rid="pharmaceutics-17-01215-f005" ref-type="fig">Figure 5</xref>C). Surprisingly, the numbers of both lymphatic (LYVE-1) and vascular (CD34) vessel counts significantly increased after PRRT treatment, suggesting the activation of a compensatory mechanism that may support tumor survival. Interestingly, PCa tumors remained positive for the hB1R target in the <sup>64</sup>Cu/NOTA-&#946;Ala-R954-treated group (<xref rid="pharmaceutics-17-01215-f005" ref-type="fig">Figure 5</xref>C), highlighting the potential to extend the number of PRRT treatment cycles to further improve therapeutic outcomes and possibly achieve complete cancer eradication.</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-17-01215"><title>4. Discussion</title><p>In this study, we demonstrated consistent expression of B1R transcripts across various cultured human PCa cell lines, CDX-derived xenografts implanted in nude mice, and resected human PCa tumor samples. Furthermore, B1R proteins were found to be overexpressed in primary PCa (and potentially in lymphatic metastases), with their expression significantly correlating with higher overall tumor grades. This observation was further validated through analyses of data from the TCGA and MSKCC databases, which also reveal that elevated B1R mRNA levels were associated with poor prognosis and reduced survival rates in PCa patients. Similarly, data from the Human Protein Atlas (HPA) show that high B1R mRNA levels were also linked to decreased survival in lung and kidney cancer patients (see <xref rid="app1-pharmaceutics-17-01215" ref-type="app">Supplementary Figure S5</xref>) [<xref rid="B55-pharmaceutics-17-01215" ref-type="bibr">55</xref>], suggesting that B1R expression may serve as an unfavorable prognostic marker in various malignancies. Collectively, the findings highlight the potential of B1R as a valuable biomarker for both the detection and therapeutic targeting of PCa. Building on this insight, we set out to develop the first <sup>64</sup>Cu-based radiotheranostic agent specifically designed to target B1R in PCa, leveraging the peptide antagonist R954. Our B1R antagonist has successfully undergone a rigorous preclinical development program, including a comprehensive evaluation of safety, efficacy (as a potential novel analgesic and anti-inflammatory agent), and ADME profiling, thereby confirming its suitability for clinical translation [<xref rid="B23-pharmaceutics-17-01215" ref-type="bibr">23</xref>]. Aligned with this objective, we provide supportive evidence that the radiolabeled <sup>64</sup>Cu/NOTA-&#946;Ala-R954 is a promising dual-purpose agent for both imaging and therapy in subcutaneous PCa mouse model with endogenous B1R expression, eliminating the need for radionuclide substitution. This is particularly important because previous studies have shown that switching the coordinating metal from an imaging radionuclide (e.g., <sup>68</sup>Ga) to a therapeutic one (e.g., <sup>111</sup>In or <sup>177</sup>Lu) can drastically alter the pharmacodynamic and pharmacokinetic properties of metalated compounds [<xref rid="B56-pharmaceutics-17-01215" ref-type="bibr">56</xref>].</p><p>Recent advancements have been made in the development of B1R-targeted radiolabeled peptides for PET imaging of cancers (see an excellent review [<xref rid="B57-pharmaceutics-17-01215" ref-type="bibr">57</xref>]). For instance, Lin&#8217;s group reported a series of peptidic B1R radiolabeled agonists and antagonists as novel PET radiotracers, using mice xenografted with HEK293T kidney cells highly overexpressing recombinant hB1R as tumor surrogates (see review [<xref rid="B57-pharmaceutics-17-01215" ref-type="bibr">57</xref>]). However, many of these B1R radiolabeled peptides have exhibited suboptimal in vitro and in vivo stability, primarily due to degradation by off-target peptidases in blood and tissues, which could contribute to false-positive results. Additionally, the potential formation of toxic radiotracer metabolites could pose a significant concern in theranostic applications, particularly in the context of high-dose radiation therapy with appropriate radionuclides. The same group also utilized the antagonist R954 to develop <sup>68</sup>Ga and <sup>18</sup>F-labeled PET agents for non-invasive B1R assessment (<sup>68</sup>Ga-DOTA-dPEG2-R954 and <sup>18</sup>F-AmBF<sub>3</sub>-Mta-dPEG<sub>2</sub>-R954) in their experimental animal model (see review [<xref rid="B57-pharmaceutics-17-01215" ref-type="bibr">57</xref>]). Similarly, Shukuri et al. recently evaluated the <sup>111</sup>In-DOTA-Ahx-R954 in a subcutaneous, natively B1R-expressing U87 brain cancer model in mice as potential PET imaging agents [<xref rid="B58-pharmaceutics-17-01215" ref-type="bibr">58</xref>]. Both studies yielded consistent positive results in terms of B1R detection [<xref rid="B57-pharmaceutics-17-01215" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceutics-17-01215" ref-type="bibr">58</xref>].</p><p>In our study, we focused on a B1R-targeting theranostics based on the R954, which displays structural differences from the previously reported compounds, more specifically in the linker, chelator, and radionuclide. As observed in numerous studies on molecularly targeted radiotherapeutics [<xref rid="B40-pharmaceutics-17-01215" ref-type="bibr">40</xref>,<xref rid="B56-pharmaceutics-17-01215" ref-type="bibr">56</xref>,<xref rid="B59-pharmaceutics-17-01215" ref-type="bibr">59</xref>], these structural components can significantly influence the binding affinity, pharmacokinetic profile, and ability to target receptor-expressing tumors in vivo. To assess the impact of these modifications, we first radiolabeled NOTA-&#946;Ala-R954 with <sup>64</sup>Cu, achieving high yield and excellent apparent molar activity. This efficient radiolabeling process ensures the production of a well-characterized tracer for subsequent pharmacological assessments. In vitro, this peptide conjugate retained strong B1R binding affinity and antagonistic potency (in the low nanomolar range), along with robust plasma stability, and significant uptake in PCa cells naturally expressing B1R. A possible mechanistic explanation for this uptake is that B1R antagonists may be passively internalized via the receptor&#8217;s constitutive, agonist-independent trafficking [<xref rid="B60-pharmaceutics-17-01215" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceutics-17-01215" ref-type="bibr">61</xref>]. Additionally, the B1R radioantagonist <sup>64</sup>Cu/NOTA-&#946;Ala-R954 showed dose-dependent anti-clonal growth effects, irrespective of the androgenic status of PCa cells. In vivo, <sup>64</sup>Cu/NOTA-&#946;Ala-R954 demonstrated exceptional stability in the systemic circulation (up to 90 min), with no detectable free <sup>64</sup>Cu or metabolites. It also exhibited efficient renal clearance, as evidenced by biodistribution analysis showing no significant accumulation in most organs over time. This observation is in line with the limited B1R expression and minimal functional activity in major organs. Like most radiolabeled peptides cleared via the kidneys, this may pose a risk of nephrotoxicity. However, renoprotective strategies, such as co-administering basic amino acids to reduce kidney retention, have proven effective in clinical PRRT [<xref rid="B62-pharmaceutics-17-01215" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceutics-17-01215" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceutics-17-01215" ref-type="bibr">64</xref>] and could be employed if necessary. Moreover, <sup>64</sup>Cu/NOTA-&#946;Ala-R954 (7.5 MBq IV) effectively detected PCa xenografts in mice, as confirmed by PET/CT imaging. Importantly, at a higher dose (65 MBq or 50 &#181;g/kg IV), it significantly inhibited tumor growth without observable adverse effects, such as weight loss, in PC3 tumor-bearing athymic nude male mice. This anticancer effect was associated with increased apoptosis (evidenced by active caspase-3) and decreased tumor cell proliferation (Ki67), along with potential compensatory angiogenic responses. In contrast, the nonradioactive <sup>Nat</sup>Cu/NOTA-&#946;Ala-R954 showed no effect at the same dose. B1R antagonists have been shown to delay tumor growth in preclinical cancer rodent models including PCa, through direct effects on cancer cells and indirect bystander effects on host stromal cells, leading to increased survival [<xref rid="B18-pharmaceutics-17-01215" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-17-01215" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-17-01215" ref-type="bibr">20</xref>,<xref rid="B65-pharmaceutics-17-01215" ref-type="bibr">65</xref>]. However, achieving these therapeutic benefits typically requires repeated administration of high doses of these antagonists. Thus, our findings underscore significant differences and distinct advantages in the therapeutic efficacy of specific B1R antagonists when combined with radionuclide therapy.</p><p>As part of our B1R-targeted theranostic plan strategy, and for comparative analysis, additional <sup>64</sup>Cu-labeled NOTA-R954 conjugates were designed, synthesized, and characterized in vitro. Their binding affinity (using B1R-HEK293 cells) and potency (using B1R-CHO-NFAT cells) were assessed under identical experimental conditions as described herein (<xref rid="app1-pharmaceutics-17-01215" ref-type="app">Supplementary Table S1</xref>). For example, the <sup>Nat</sup>Cu-labeled NOTA-R954 conjugate without the &#946;Ala linker retained its ability to bind and effectively antagonize B1R (see peptide MAB7090: IC<sub>50</sub> values 13 nM and 10 nM, respectively), suggesting that the linker is not essential for its function. Similarly, the <sup>Nat</sup>Cu-labeled NOTA-R954 conjugate, in which NOTA conjugation occurred at the &#949;-amino group in the side chain of the extended lysine-containing peptide (Ac-Lys(<sup>Nat</sup>Cu/NOTA)-R954) rather than at the peptide&#8217;s N-terminus, also maintained high affinity toward B1R (see peptide MAB8082: IC<sub>50</sub> value: 19 nM). In parallel, we expanded our analysis by developing new NOTA&#8211;agonist peptide conjugates based on our previously developed biostable, high-affinity, and potent B1R agonists for comparative evaluation (<xref rid="app1-pharmaceutics-17-01215" ref-type="app">Supplementary Table S2</xref>) [<xref rid="B43-pharmaceutics-17-01215" ref-type="bibr">43</xref>,<xref rid="B66-pharmaceutics-17-01215" ref-type="bibr">66</xref>]. This includes the peptide agonist NG29, which exhibits superior safety and tolerability compared to the antagonist R954 [<xref rid="B43-pharmaceutics-17-01215" ref-type="bibr">43</xref>,<xref rid="B66-pharmaceutics-17-01215" ref-type="bibr">66</xref>]. Interestingly, NG29 may also enhance tumor vascular permeability, potentially facilitating better radiopharmaceutical penetration, retention, and deeper tumor infiltration, and ultimately contributing to enhanced radiotherapy efficacy [<xref rid="B33-pharmaceutics-17-01215" ref-type="bibr">33</xref>,<xref rid="B37-pharmaceutics-17-01215" ref-type="bibr">37</xref>,<xref rid="B67-pharmaceutics-17-01215" ref-type="bibr">67</xref>]. Notably, the two related potent Cu-labeled theranostic agonist prototypes, <sup>Nat</sup>Cu/NOTA-&#946;Ala-Lys[Hyp<sup>3</sup>,Igl<sup>5</sup>,<sc>d</sc>Phe<sup>8</sup>]desArg<sup>9</sup>BK (MAB7095: IC<sub>50</sub> value: 1.3 nM) and Sar-Lys(<sup>Nat</sup>Cu/NOTA)-Lys[<sc>d</sc>Phe<sup>8</sup>]desArg<sup>9</sup>BK (MAB8084; IC<sub>50</sub> value: 2.6 nM), stand out as promising candidates. The theranostic potential of these <sup>64</sup>Cu-labelled compounds could be further evaluated in future in vivo studies using PET imaging and PRRT to identify the most suitable theranostic candidate for both diagnostic and therapeutic applications against certain types of solid cancer.</p><p>In conclusion, our study further emphasized the clinical relevance of B1R in PCa. Here, we have developed the first effective kinin B1R-targeting, R954-based theranostic agent for PCa, featuring favorable pharmacological properties, with the ability to detect and treat prostate tumor lesions in preclinical settings. Further research is needed to determine whether the promising theranostic agent <sup>64</sup>Cu/NOTA-&#946;Ala-R954, along with other candidates described herein, can drive advancements in B1R-positive PCa and other malignancies.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank J. Lafontaine for her technical assistance with qPCR assays. The PET imaging and biodistribution studies were conducted at the Sherbrooke Molecular Imaging Centre (CIMS). We thank O. Sarrhini and G. Richard from the CIMS/CRCHUS Image Visualization and Analysis Platform (PAVI) for their technical assistance in the analysis of PET data.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-17-01215"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics17091215/s1">https://www.mdpi.com/article/10.3390/pharmaceutics17091215/s1</uri>, Figure S1: Validation of target specificity of the anti-B1R antibodies, LS-A799 and AS434, in HEK293 cells stably transfected with either mock expression vector (control) or human B1R.; Figure S2: Representative images corresponding to the different immunoscores for prostate epithelial cells and the corresponding normal IgG control staining; Figure S3: HPLC and mass spectrometry analyses of the synthesized peptides R954 and NOTA-&#946;Ala-R954; Figure S4: Flow cytometry analysis of B1R expression in PC3 and LNCap cells; Figure S5: Kaplan&#8211;Meier survival analysis of the association between hB1R expression and survival probability in lung and kidney cancers; Table S1: Binding affinity and potency estimates of novel NOTA-R954 peptide conjugates in hB1R-stably expressing HEK293 and CHO cells; Table S2: Binding affinity and potency estimates of novel NOTA&#8211;agonist peptide conjugates in hB1R-stably expressing HEK293 and CHO cells.</p><supplementary-material id="pharmaceutics-17-01215-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-17-01215-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>F.G. and B.G. conceived and designed the study; S.G.K., M.S., C.D., F.C., V.D.-P., M.-E.N.-T., S.A.-M. and F.G. performed the experiments and acquired the data; S.G.K., M.S., C.D., F.C., V.D.-P., S.G., B.G. and F.G. analyzed and interpreted the data; S.G., R.S. and Y.D. provided some reagents; B.G., Y.D. and F.G. were responsible for supervision and funding acquisition; S.G.K., M.S., F.C. and F.G. wrote the manuscript with input from all authors. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>All applicable ethical approvals for studies involving human participants and animal experiments were obtained and are detailed in the respective methods sections of this manuscript. This study was conducted in accordance with the Declaration of Helsinki and approved by the Human Ethics Committee at the Centre de Recherche du CHUS (protocol numbers 2013-490, 24 October 2012; 97-14; 21 March 1997). All mouse experimentation was approved by the Animal Care Committee (CPA) of the Faculty of Medicine and Health Sciences (FMSS), Universit&#233; de Sherbrooke (protocol numbers #392-15BR, 14 July 2015; #2019-2371, 5 March 2020) and conducted in accordance with the guidelines of Canadian Council on Animal Care.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained for all applicable studies and is detailed in the relevant methods section of this manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data generated or analysed during this study are included in this published article and its <xref rid="app1-pharmaceutics-17-01215" ref-type="app">supplementary information</xref> files or are available from the corresponding author upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>R.S., B.G., and F.G. are co-inventors on a patent owned by the Universit&#233; de Sherbrooke (US 11,213,597 B2), which describes the use of new kinin B1R theranostic peptides for dual imaging and radiotherapy applications in solid cancers. Author Fr&#233;d&#233;ric Couture was employed by the company TransBIOTech. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCa</td><td align="left" valign="middle" rowspan="1" colspan="1">Prostate cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDG</td><td align="left" valign="middle" rowspan="1" colspan="1"><sup>18</sup>F-fluorodeoxyglucose</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PSA</td><td align="left" valign="middle" rowspan="1" colspan="1">Prostate specific antigen</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DRE</td><td align="left" valign="middle" rowspan="1" colspan="1">Digital rectal examination</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MRI</td><td align="left" valign="middle" rowspan="1" colspan="1">Magnetic resonance imaging</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GPCR</td><td align="left" valign="middle" rowspan="1" colspan="1">G protein-coupled receptors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PET</td><td align="left" valign="middle" rowspan="1" colspan="1">Positron emission tomography</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TMA</td><td align="left" valign="middle" rowspan="1" colspan="1">Tissue microarray</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IHC</td><td align="left" valign="middle" rowspan="1" colspan="1">Immunohistochemistry</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FFPE</td><td align="left" valign="middle" rowspan="1" colspan="1">Formalin-fixed paraffin-embedded</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DMEM</td><td align="left" valign="middle" rowspan="1" colspan="1">Dulbecco&#8217;s modified Eagle medium</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FBS</td><td align="left" valign="middle" rowspan="1" colspan="1">Fetal bovine serum</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PIN</td><td align="left" valign="middle" rowspan="1" colspan="1">Prostatic intraepithelial neoplasia</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmaceutics-17-01215"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer statistics, 2020</article-title><source>CA A Cancer J. Clin.</source><year>2020</year><volume>70</volume><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3322/caac.21590</pub-id><pub-id pub-id-type="pmid">31912902</pub-id></element-citation></ref><ref id="B2-pharmaceutics-17-01215"><label>2.</label><element-citation publication-type="webpage"><article-title>Canadian Cancer Society: Prostate Cancer Statistics</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cancer.ca/en/cancer-information/cancer-types/prostate/statistics" ext-link-type="uri">https://cancer.ca/en/cancer-information/cancer-types/prostate/statistics</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-10">(accessed on 10 March 2024)</date-in-citation></element-citation></ref><ref id="B3-pharmaceutics-17-01215"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bednarova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lindenberg</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Vinsensia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zuiani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Choyke</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Turkbey</surname><given-names>B.</given-names></name></person-group><article-title>Positron emission tomography (PET) in primary prostate cancer staging and risk assessment</article-title><source>Transl. Androl. Urol.</source><year>2017</year><volume>6</volume><fpage>413</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.21037/tau.2017.03.53</pub-id><pub-id pub-id-type="pmid">28725583</pub-id><pub-id pub-id-type="pmcid">PMC5503952</pub-id></element-citation></ref><ref id="B4-pharmaceutics-17-01215"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kania</surname><given-names>E.</given-names></name><name name-style="western"><surname>Janica</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nesterowicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Modzelewski</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cybulski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Janica</surname><given-names>J.</given-names></name></person-group><article-title>Advances and Challenges in Prostate Cancer Diagnosis: A Comprehensive Review</article-title><source>Cancers</source><year>2025</year><volume>17</volume><elocation-id>2137</elocation-id><pub-id pub-id-type="doi">10.3390/cancers17132137</pub-id><pub-id pub-id-type="pmid">40647437</pub-id><pub-id pub-id-type="pmcid">PMC12248846</pub-id></element-citation></ref><ref id="B5-pharmaceutics-17-01215"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soeterik</surname><given-names>T.F.W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Van den Bergh</surname><given-names>R.C.N.</given-names></name><name name-style="western"><surname>Kesch</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zattoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Falagario</surname><given-names>U.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miszczyk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fasulo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Personalised Prostate Cancer Diagnosis: Evaluating Biomarker-based Approaches to Reduce Unnecessary Magnetic Resonance Imaging and Biopsy Procedures</article-title><source>Eur. Urol. Open Sci.</source><year>2025</year><volume>75</volume><fpage>106</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.euros.2025.03.006</pub-id><pub-id pub-id-type="pmid">40291786</pub-id><pub-id pub-id-type="pmcid">PMC12032181</pub-id></element-citation></ref><ref id="B6-pharmaceutics-17-01215"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sch&#246;der</surname><given-names>H.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J.S.</given-names></name></person-group><article-title>Radiotheranostics in oncology: Current challenges and emerging opportunities</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2022</year><volume>19</volume><fpage>534</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/s41571-022-00652-y</pub-id><pub-id pub-id-type="pmid">35725926</pub-id><pub-id pub-id-type="pmcid">PMC10585450</pub-id></element-citation></ref><ref id="B7-pharmaceutics-17-01215"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeelani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Maheswaran</surname><given-names>T.</given-names></name><name name-style="western"><surname>Asokan</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Dany</surname><given-names>A.</given-names></name><name name-style="western"><surname>Anand</surname><given-names>B.</given-names></name></person-group><article-title>Theranostics: A treasured tailor for tomorrow</article-title><source>J. Pharm. Bioallied Sci.</source><year>2014</year><volume>6</volume><issue>(Suppl. S1)</issue><fpage>S6</fpage><lpage>S8</lpage><pub-id pub-id-type="doi">10.4103/0975-7406.137249</pub-id><pub-id pub-id-type="pmid">25210387</pub-id><pub-id pub-id-type="pmcid">PMC4157283</pub-id></element-citation></ref><ref id="B8-pharmaceutics-17-01215"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorsam</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Gutkind</surname><given-names>J.S.</given-names></name></person-group><article-title>G-protein-coupled receptors and cancer</article-title><source>Nat. Rev. Cancer</source><year>2007</year><volume>7</volume><fpage>79</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1038/nrc2069</pub-id><pub-id pub-id-type="pmid">17251915</pub-id></element-citation></ref><ref id="B9-pharmaceutics-17-01215"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maecke</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Okarvi</surname><given-names>S.M.</given-names></name></person-group><article-title>Radiolabeled peptides: Valuable tools for the detection and treatment of cancer</article-title><source>Theranostics</source><year>2012</year><volume>2</volume><fpage>481</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.7150/thno.4024</pub-id><pub-id pub-id-type="pmid">22737187</pub-id><pub-id pub-id-type="pmcid">PMC3364555</pub-id></element-citation></ref><ref id="B10-pharmaceutics-17-01215"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lappano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maggiolini</surname><given-names>M.</given-names></name></person-group><article-title>G protein-coupled receptors: Novel targets for drug discovery in cancer</article-title><source>Nat. Rev. Drug Discov.</source><year>2011</year><volume>10</volume><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">21193867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd3320</pub-id></element-citation></ref><ref id="B11-pharmaceutics-17-01215"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohtavinejad</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ardestani</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Khalaj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pormohammad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Najafi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bitarafan-Rajabi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hajiramezanali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amanlou</surname><given-names>M.</given-names></name></person-group><article-title>Application of radiolabeled peptides in tumor imaging and therapy</article-title><source>Life Sci.</source><year>2020</year><volume>258</volume><fpage>118206</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.118206</pub-id><pub-id pub-id-type="pmid">32758623</pub-id></element-citation></ref><ref id="B12-pharmaceutics-17-01215"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dumont</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Tamma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>F.</given-names></name><name name-style="western"><surname>Borkowski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reubi</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Maecke</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Mansi</surname><given-names>R.</given-names></name></person-group><article-title>Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin</article-title><source>J. Nucl. Med.</source><year>2013</year><volume>54</volume><fpage>762</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.2967/jnumed.112.112169</pub-id><pub-id pub-id-type="pmid">23492884</pub-id></element-citation></ref><ref id="B13-pharmaceutics-17-01215"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maina</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bergsma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>D.</given-names></name><name name-style="western"><surname>Charalambidis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Krenning</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Nock</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baum</surname><given-names>R.P.</given-names></name></person-group><article-title>Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [<sup>68</sup>Ga]SB3 and PET/CT</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2016</year><volume>43</volume><fpage>964</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1007/s00259-015-3232-1</pub-id><pub-id pub-id-type="pmid">26631238</pub-id></element-citation></ref><ref id="B14-pharmaceutics-17-01215"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nock</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Kaloudi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lymperis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giarika</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Klette</surname><given-names>I.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krenning</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maina</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results</article-title><source>J. Nucl. Med.</source><year>2017</year><volume>58</volume><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.2967/jnumed.116.178889</pub-id><pub-id pub-id-type="pmid">27493272</pub-id></element-citation></ref><ref id="B15-pharmaceutics-17-01215"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tripathi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trabulsi</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Gomella</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>McCue</surname><given-names>P.</given-names></name><name name-style="western"><surname>Intenzo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Birbe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gandhe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thakur</surname><given-names>M.</given-names></name></person-group><article-title>VPAC1 Targeted <sup>64</sup>Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man</article-title><source>Urology</source><year>2016</year><volume>88</volume><fpage>111</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2015.10.012</pub-id><pub-id pub-id-type="pmid">26519886</pub-id><pub-id pub-id-type="pmcid">PMC4788593</pub-id></element-citation></ref><ref id="B16-pharmaceutics-17-01215"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wieser</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mansi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grosu</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Schultze-Seemann</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dumont-Walter</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Maecke</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Reubi</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>W.A.</given-names></name></person-group><article-title>Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men</article-title><source>Theranostics</source><year>2014</year><volume>4</volume><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.7150/thno.7324</pub-id><pub-id pub-id-type="pmid">24578724</pub-id><pub-id pub-id-type="pmcid">PMC3936293</pub-id></element-citation></ref><ref id="B17-pharmaceutics-17-01215"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>R.</given-names></name></person-group><article-title>New frontiers in molecular imaging using peptide-based radiopharmaceuticals for prostate cancer</article-title><source>Front. Chem.</source><year>2020</year><volume>8</volume><elocation-id>583309</elocation-id><pub-id pub-id-type="doi">10.3389/fchem.2020.583309</pub-id><pub-id pub-id-type="pmid">33335885</pub-id><pub-id pub-id-type="pmcid">PMC7736158</pub-id></element-citation></ref><ref id="B18-pharmaceutics-17-01215"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Costa</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Sirois</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tannock</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Chammas</surname><given-names>R.</given-names></name></person-group><article-title>The role of kinin receptors in cancer and therapeutic opportunities</article-title><source>Cancer Lett.</source><year>2014</year><volume>345</volume><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2013.12.009</pub-id><pub-id pub-id-type="pmid">24333733</pub-id></element-citation></ref><ref id="B19-pharmaceutics-17-01215"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Figueroa</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Ehrenfeld</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bhoola</surname><given-names>K.D.</given-names></name></person-group><article-title>Kinin receptors as targets for cancer therapy</article-title><source>Expert Opin. Ther. Targets</source><year>2012</year><volume>16</volume><fpage>299</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1517/14728222.2012.662957</pub-id><pub-id pub-id-type="pmid">22339271</pub-id></element-citation></ref><ref id="B20-pharmaceutics-17-01215"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gera</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Fortin</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Morissette</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marceau</surname><given-names>F.</given-names></name></person-group><article-title>Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958</article-title><source>Int. Immunopharmacol.</source><year>2008</year><volume>8</volume><fpage>289</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2007.06.006</pub-id><pub-id pub-id-type="pmid">18182242</pub-id></element-citation></ref><ref id="B21-pharmaceutics-17-01215"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pesquero</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Heppenstall</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Stucky</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J.A.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Walther</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Pesquero</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Paiva</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Calixto</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2000</year><volume>97</volume><fpage>8140</fpage><lpage>8145</lpage><pub-id pub-id-type="doi">10.1073/pnas.120035997</pub-id><pub-id pub-id-type="pmid">10859349</pub-id><pub-id pub-id-type="pmcid">PMC16683</pub-id></element-citation></ref><ref id="B22-pharmaceutics-17-01215"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taub</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leeb-Lundberg</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Madden</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Daaka</surname><given-names>Y.</given-names></name></person-group><article-title>Bradykinin receptor subtype 1 expression and function in prostate cancer</article-title><source>Cancer Res.</source><year>2003</year><volume>63</volume><fpage>2037</fpage><lpage>2041</lpage><pub-id pub-id-type="pmid">12727816</pub-id></element-citation></ref><ref id="B23-pharmaceutics-17-01215"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gobeil</surname><given-names>F.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Sirois</surname><given-names>P.</given-names></name><name name-style="western"><surname>Regoli</surname><given-names>D.</given-names></name></person-group><article-title>Preclinical pharmacology, metabolic stability, pharmacokinetics and toxicology of the peptidic kinin B1 receptor antagonist R-954</article-title><source>Peptides</source><year>2014</year><volume>52</volume><fpage>82</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2013.12.009</pub-id><pub-id pub-id-type="pmid">24361511</pub-id></element-citation></ref><ref id="B24-pharmaceutics-17-01215"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neugebauer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Blais</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Halle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Filteau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Regoli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gobeil</surname><given-names>F.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Kinin B1 receptor antagonists with multi-enzymatic resistance properties</article-title><source>Can. J. Physiol. Pharmacol.</source><year>2002</year><volume>80</volume><fpage>287</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1139/y02-053</pub-id><pub-id pub-id-type="pmid">12025963</pub-id></element-citation></ref><ref id="B25-pharmaceutics-17-01215"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gobeil</surname><given-names>F.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Charland</surname><given-names>S.</given-names></name><name name-style="western"><surname>Filteau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perron</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Neugebauer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Regoli</surname><given-names>D.</given-names></name></person-group><article-title>Kinin B1 receptor antagonists containing alpha-methyl-L-phenylalanine: In vitro and in vivo antagonistic activities</article-title><source>Hypertension</source><year>1999</year><volume>33</volume><fpage>823</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.33.3.823</pub-id><pub-id pub-id-type="pmid">10082494</pub-id></element-citation></ref><ref id="B26-pharmaceutics-17-01215"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gobeil</surname><given-names>F.</given-names></name><name name-style="western"><surname>Neugebauer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Filteau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jukic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Allogho</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Pheng</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Nguyen-Le</surname><given-names>X.K.</given-names></name><name name-style="western"><surname>Blouin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Regoli</surname><given-names>D.</given-names></name></person-group><article-title>Structure-activity studies of B1 receptor-related peptides. Antagonists</article-title><source>Hypertension</source><year>1996</year><volume>28</volume><fpage>833</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">8901831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.hyp.28.5.833</pub-id></element-citation></ref><ref id="B27-pharmaceutics-17-01215"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biggin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hedt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jeffery</surname><given-names>C.</given-names></name></person-group><article-title>Radiological properties of Next Generation Theranostics (Cu-64/Cu-67)</article-title><source>J. Nucl. Med.</source><year>2017</year><volume>58</volume><issue>(Suppl. S1)</issue><fpage>1014</fpage></element-citation></ref><ref id="B28-pharmaceutics-17-01215"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boschi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Janevik-Ivanovska</surname><given-names>E.</given-names></name><name name-style="western"><surname>Duatti</surname><given-names>A.</given-names></name></person-group><article-title>The emerging role of copper-64 radiopharmaceuticals as cancer theranostics</article-title><source>Drug Discov. Today</source><year>2018</year><volume>23</volume><fpage>1489</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2018.04.002</pub-id><pub-id pub-id-type="pmid">29635027</pub-id></element-citation></ref><ref id="B29-pharmaceutics-17-01215"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Follacchio</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>De Feo</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>De Vincentis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Monteleone</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liberatore</surname><given-names>M.</given-names></name></person-group><article-title>Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings</article-title><source>Curr. RadioPharm.</source><year>2018</year><volume>11</volume><fpage>22</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">29231149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1874471011666171211161851</pub-id></element-citation></ref><ref id="B30-pharmaceutics-17-01215"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chhabra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thakur</surname><given-names>M.L.</given-names></name></person-group><article-title>Theragnostic radionuclide pairs for prostate cancer Management: 64Cu/67Cu, can be a budding hot duo</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>2787</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10112787</pub-id><pub-id pub-id-type="pmid">36359312</pub-id><pub-id pub-id-type="pmcid">PMC9687163</pub-id></element-citation></ref><ref id="B31-pharmaceutics-17-01215"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#233;langer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bovenzi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cote</surname><given-names>J.</given-names></name><name name-style="western"><surname>Neugebauer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Amblard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lammek</surname><given-names>B.</given-names></name><name name-style="western"><surname>Savard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gobeil</surname><given-names>F.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Structure-activity relationships of novel peptide agonists of the human bradykinin B2 receptor</article-title><source>Peptides</source><year>2009</year><volume>30</volume><fpage>777</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2008.12.003</pub-id><pub-id pub-id-type="pmid">19111586</pub-id></element-citation></ref><ref id="B32-pharmaceutics-17-01215"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blaukat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Herzer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nash</surname><given-names>N.</given-names></name><name name-style="western"><surname>Muller-Esterl</surname><given-names>W.</given-names></name></person-group><article-title>Overexpression and functional characterization of kinin receptors reveal subtype-specific phosphorylation</article-title><source>Biochemistry</source><year>1999</year><volume>38</volume><fpage>1300</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1021/bi981727r</pub-id><pub-id pub-id-type="pmid">9930991</pub-id></element-citation></ref><ref id="B33-pharmaceutics-17-01215"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>C&#244;t&#233;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bovenzi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Savard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dubuc</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fortier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neugebauer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tremblay</surname><given-names>L.</given-names></name><name name-style="western"><surname>Muller-Esterl</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tsanaclis</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lepage</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Induction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat model</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e37485</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0037485</pub-id><pub-id pub-id-type="pmid">22629405</pub-id><pub-id pub-id-type="pmcid">PMC3357387</pub-id></element-citation></ref><ref id="B34-pharmaceutics-17-01215"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hieronymus</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gopalan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Carver</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Arora</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cerami</surname><given-names>E.</given-names></name><name name-style="western"><surname>Reva</surname><given-names>B.</given-names></name></person-group><article-title>Integrative genomic profiling of human prostate cancer</article-title><source>Cancer Cell</source><year>2010</year><volume>18</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.05.026</pub-id><pub-id pub-id-type="pmid">20579941</pub-id><pub-id pub-id-type="pmcid">PMC3198787</pub-id></element-citation></ref><ref id="B35-pharmaceutics-17-01215"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hadaschik</surname><given-names>B.</given-names></name><name name-style="western"><surname>Siegers</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Fiebig</surname><given-names>H.-H.</given-names></name><name name-style="western"><surname>Sch&#252;ler</surname><given-names>J.</given-names></name></person-group><article-title>Characterization of colon cancer cells: A functional approach characterizing CD133 as a potential stem cell marker</article-title><source>BMC Cancer</source><year>2012</year><volume>12</volume><fpage>96</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-12-96</pub-id><pub-id pub-id-type="pmid">22433494</pub-id><pub-id pub-id-type="pmcid">PMC3368744</pub-id></element-citation></ref><ref id="B36-pharmaceutics-17-01215"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCarthy</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Shefer</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Klinkowstein</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Bass</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Margeneau</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>M.J.</given-names></name></person-group><article-title>Efficient production of high specific activity 64Cu using a biomedical cyclotron</article-title><source>Nucl. Med. Biol.</source><year>1997</year><volume>24</volume><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/S0969-8051(96)00157-6</pub-id><pub-id pub-id-type="pmid">9080473</pub-id></element-citation></ref><ref id="B37-pharmaceutics-17-01215"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sikpa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Whittingstall</surname><given-names>L.</given-names></name><name name-style="western"><surname>Savard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lebel</surname><given-names>R.</given-names></name><name name-style="western"><surname>C&#244;t&#233;</surname><given-names>J.</given-names></name><name name-style="western"><surname>McManus</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chemtob</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fortin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lepage</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gobeil</surname><given-names>F.</given-names></name></person-group><article-title>Pharmacological Modulation of Blood&#8211;Brain Barrier Permeability by Kinin Analogs in Normal and Pathologic Conditions</article-title><source>Pharmaceuticals</source><year>2020</year><volume>13</volume><elocation-id>279</elocation-id><pub-id pub-id-type="doi">10.3390/ph13100279</pub-id><pub-id pub-id-type="pmid">33003415</pub-id><pub-id pub-id-type="pmcid">PMC7650794</pub-id></element-citation></ref><ref id="B38-pharmaceutics-17-01215"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gagnon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Savard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>T.M.H.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moquin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tremblay</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roucou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dory</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gobeil</surname><given-names>F.</given-names></name></person-group><article-title>Evaluation of Novel B1R/B2R Agonists Containing TRIOZAN&#8482; Nanoparticles for Targeted Brain Delivery of Antibodies in a Mouse Model of Alzheimer Disease</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>5206</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28135206</pub-id><pub-id pub-id-type="pmid">37446867</pub-id><pub-id pub-id-type="pmcid">PMC10343654</pub-id></element-citation></ref><ref id="B39-pharmaceutics-17-01215"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Couture</surname><given-names>F.</given-names></name><name name-style="western"><surname>Levesque</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dumulon-Perreault</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ait-Mohand</surname><given-names>S.</given-names></name><name name-style="western"><surname>D&#8217;Anjou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Day</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guerin</surname><given-names>B.</given-names></name></person-group><article-title>PACE4-based molecular targeting of prostate cancer using an engineered <sup>64</sup>Cu-radiolabeled peptide inhibitor</article-title><source>Neoplasia</source><year>2014</year><volume>16</volume><fpage>634</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2014.07.010</pub-id><pub-id pub-id-type="pmid">25220591</pub-id><pub-id pub-id-type="pmcid">PMC4235008</pub-id></element-citation></ref><ref id="B40-pharmaceutics-17-01215"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fournier</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dumulon-Perreault</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ait-Mohand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tremblay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lecomte</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gu&#233;rin</surname><given-names>B.</given-names></name></person-group><article-title>Novel radiolabeled peptides for breast and prostate tumor PET imaging: <sup>64</sup>Cu/and <sup>68</sup>Ga/NOTA-PEG-[D-Tyr(6),betaAla(11),Thi(13),Nle(14)]BBN(6-14)</article-title><source>Bioconjug Chem</source><year>2012</year><volume>23</volume><fpage>1687</fpage><lpage>1693</lpage><pub-id pub-id-type="doi">10.1021/bc3002437</pub-id><pub-id pub-id-type="pmid">22770480</pub-id></element-citation></ref><ref id="B41-pharmaceutics-17-01215"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gobeil</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pheng</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Badini</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nguyen-Le</surname><given-names>X.K.</given-names></name><name name-style="western"><surname>Pizard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rizzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blouin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Regoli</surname><given-names>D.</given-names></name></person-group><article-title>Receptors for kinins in the human isolated umbilical vein</article-title><source>Br. J. Pharmacol.</source><year>1996</year><volume>118</volume><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.1996.tb15401.x</pub-id><pub-id pub-id-type="pmid">8735629</pub-id><pub-id pub-id-type="pmcid">PMC1909628</pub-id></element-citation></ref><ref id="B42-pharmaceutics-17-01215"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Regoli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nsa Allogho</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rizzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gobeil</surname><given-names>F.J.</given-names></name></person-group><article-title>Bradykinin receptors and their antagonists</article-title><source>Eur. J. Pharmacol.</source><year>1998</year><volume>348</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(98)00165-4</pub-id><pub-id pub-id-type="pmid">9650825</pub-id></element-citation></ref><ref id="B43-pharmaceutics-17-01215"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>C&#244;t&#233;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Savard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bovenzi</surname><given-names>V.</given-names></name><name name-style="western"><surname>B&#233;langer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Neugebauer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Larouche</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dubuc</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gobeil</surname><given-names>F.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Novel kinin B1 receptor agonists with improved pharmacological profiles</article-title><source>Peptides</source><year>2009</year><volume>30</volume><fpage>788</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2008.12.018</pub-id><pub-id pub-id-type="pmid">19150636</pub-id></element-citation></ref><ref id="B44-pharmaceutics-17-01215"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Caruano</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>VanderWaal</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.J.</given-names></name></person-group><article-title>Subcellular Localization of Radiolabeled Somatostatin Analogues: Implications for Targeted Radiotherapy of Cancer</article-title><source>Cancer Res.</source><year>2003</year><volume>63</volume><fpage>6864</fpage><lpage>6869</lpage><pub-id pub-id-type="pmid">14583484</pub-id></element-citation></ref><ref id="B45-pharmaceutics-17-01215"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubuc</surname><given-names>C.</given-names></name><name name-style="western"><surname>Savard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bovenzi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lessard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cote</surname><given-names>J.</given-names></name><name name-style="western"><surname>Neugebauer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Geha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chemtob</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gobeil</surname><given-names>F.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Antitumor activity of cell-penetrant kinin B1 receptor antagonists in human triple-negative breast cancer cells</article-title><source>J. Cell. Physiol.</source><year>2019</year><volume>234</volume><fpage>2851</fpage><lpage>2865</lpage><pub-id pub-id-type="doi">10.1002/jcp.27103</pub-id><pub-id pub-id-type="pmid">30132865</pub-id></element-citation></ref><ref id="B46-pharmaceutics-17-01215"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergeron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cadorette</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tetrault</surname><given-names>M.-A.</given-names></name><name name-style="western"><surname>Beaudoin</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Leroux</surname><given-names>J.-D.</given-names></name><name name-style="western"><surname>Fontaine</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lecomte</surname><given-names>R.</given-names></name></person-group><article-title>Imaging performance of LabPET APD-based digital PET scanners for pre-clinical research</article-title><source>Phys. Med. Biol</source><year>2014</year><volume>59</volume><elocation-id>661</elocation-id><pub-id pub-id-type="doi">10.1088/0031-9155/59/3/661</pub-id><pub-id pub-id-type="pmid">24442278</pub-id></element-citation></ref><ref id="B47-pharmaceutics-17-01215"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khosravifarsani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ait-Mohand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paquette</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sanche</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gu&#233;rin</surname><given-names>B.</given-names></name></person-group><article-title>In vivo behavior of [<sup>64</sup>Cu] NOTA-terpyridine platinum, a novel chemo-radio-theranostic agent for imaging, and therapy of colorectal cancer</article-title><source>Front. Med.</source><year>2022</year><volume>9</volume><elocation-id>975213</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2022.975213</pub-id><pub-id pub-id-type="pmcid">PMC9549809</pub-id><pub-id pub-id-type="pmid">36226156</pub-id></element-citation></ref><ref id="B48-pharmaceutics-17-01215"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Connett</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.-W.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Zinn</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Philpott</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>M.J.</given-names></name></person-group><article-title>Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: A comparison with 67Cu</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1996</year><volume>93</volume><fpage>6814</fpage><lpage>6818</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.13.6814</pub-id><pub-id pub-id-type="pmid">8692901</pub-id><pub-id pub-id-type="pmcid">PMC39110</pub-id></element-citation></ref><ref id="B49-pharmaceutics-17-01215"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#233;tivier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Le Sa&#235;c</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gaschet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chauvet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marionneau-Lambot</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hofgaard</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Bogen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pineau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Le Bris</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tripier</surname><given-names>R.</given-names></name></person-group><article-title>Preclinical evaluation of a <sup>64</sup>Cu-based theranostic approach in a murine model of multiple myeloma</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>1817</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15071817</pub-id><pub-id pub-id-type="pmid">37514004</pub-id><pub-id pub-id-type="pmcid">PMC10385603</pub-id></element-citation></ref><ref id="B50-pharmaceutics-17-01215"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milot</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Belissant-Benesty</surname><given-names>O.</given-names></name><name name-style="western"><surname>Dumulon-Perreault</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ait-Mohand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Geha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Richard</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Guerin</surname><given-names>B.</given-names></name></person-group><article-title>Theranostic <sup>64</sup>Cu-DOTHA<sup>2</sup>-PSMA allows low toxicity radioligand therapy in mice prostate cancer model</article-title><source>Front. Oncol.</source><year>2023</year><volume>13</volume><elocation-id>1073491</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2023.1073491</pub-id><pub-id pub-id-type="pmid">36741017</pub-id><pub-id pub-id-type="pmcid">PMC9889868</pub-id></element-citation></ref><ref id="B51-pharmaceutics-17-01215"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshii</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Furukawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kiyono</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshii</surname><given-names>H.</given-names></name><name name-style="western"><surname>Asai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okazawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Fujibayashi</surname><given-names>Y.</given-names></name></person-group><article-title>Internal radiotherapy with copper-64-diacetyl-bis (N4-methylthiosemicarbazone) reduces CD133+ highly tumorigenic cells and metastatic ability of mouse colon carcinoma</article-title><source>Nuc. Med. Biol.</source><year>2011</year><volume>38</volume><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.nucmedbio.2010.08.009</pub-id><pub-id pub-id-type="pmid">21315269</pub-id></element-citation></ref><ref id="B52-pharmaceutics-17-01215"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowsett</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>T.O.</given-names></name><name name-style="western"><surname>A&#8217;Hern</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coombes</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Cuzick</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Hugh</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lively</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer working group</article-title><source>J. Natl. Cancer Inst.</source><year>2011</year><volume>103</volume><fpage>1656</fpage><lpage>1664</lpage><pub-id pub-id-type="doi">10.1093/jnci/djr393</pub-id><pub-id pub-id-type="pmid">21960707</pub-id><pub-id pub-id-type="pmcid">PMC3216967</pub-id></element-citation></ref><ref id="B53-pharmaceutics-17-01215"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gobeil Jr</surname><given-names>F.</given-names></name><name name-style="western"><surname>Savard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dumulon-Perreault</surname><given-names>V.</given-names></name><name name-style="western"><surname>Croteau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Croteau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Guerin</surname><given-names>B.</given-names></name></person-group><article-title>Theranostic potential of a new [<sup>64</sup>Cu]-radiolabeled R-954 conjugate for kinin B1R positive tumors</article-title><source>J. Nucl. Med.</source><year>2016</year><volume>57</volume><issue>(Suppl. S2)</issue><fpage>1164</fpage></element-citation></ref><ref id="B54-pharmaceutics-17-01215"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomes</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Nedel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>N&#246;r</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Tarquinio</surname><given-names>S.B.C.</given-names></name></person-group><article-title>Tumor angiogenesis and lymphangiogenesis: Tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms</article-title><source>Life Sci.</source><year>2013</year><volume>92</volume><fpage>101</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2012.10.008</pub-id><pub-id pub-id-type="pmid">23178150</pub-id><pub-id pub-id-type="pmcid">PMC3740377</pub-id></element-citation></ref><ref id="B55-pharmaceutics-17-01215"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uhlen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sjostedt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fagerberg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bidkhori</surname><given-names>G.</given-names></name><name name-style="western"><surname>Benfeitas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Arif</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Edfors</surname><given-names>F.</given-names></name><etal/></person-group><article-title>A pathology atlas of the human cancer transcriptome</article-title><source>Science</source><year>2017</year><volume>357</volume><fpage>6352</fpage><pub-id pub-id-type="doi">10.1126/science.aan2507</pub-id><pub-id pub-id-type="pmid">28818916</pub-id></element-citation></ref><ref id="B56-pharmaceutics-17-01215"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lymperis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kaloudi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sallegger</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>Krenning</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maina</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nock</surname><given-names>B.A.</given-names></name></person-group><article-title>Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin</article-title><source>Bioconjug. Chem.</source><year>2018</year><volume>29</volume><fpage>1774</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.8b00225</pub-id><pub-id pub-id-type="pmid">29664606</pub-id></element-citation></ref><ref id="B57-pharmaceutics-17-01215"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>D.</given-names></name><name name-style="western"><surname>B&#233;nard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K.-S.</given-names></name></person-group><article-title>A systematic review of molecular imaging agents targeting bradykinin B1 and B2 receptors</article-title><source>Pharmaceuticals</source><year>2020</year><volume>13</volume><elocation-id>199</elocation-id><pub-id pub-id-type="doi">10.3390/ph13080199</pub-id><pub-id pub-id-type="pmid">32824565</pub-id><pub-id pub-id-type="pmcid">PMC7464927</pub-id></element-citation></ref><ref id="B58-pharmaceutics-17-01215"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shukuri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Onoe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karube</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mokudai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wakui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Asano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Murai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Akizawa</surname><given-names>H.</given-names></name></person-group><article-title>Assessment of Radiolabelled Derivatives of R954 for Detection of Bradykinin B1 Receptor in Cancer Cells: Studies on Glioblastoma Xenografts in Mice</article-title><source>Pharmaceuticals</source><year>2024</year><volume>17</volume><elocation-id>902</elocation-id><pub-id pub-id-type="doi">10.3390/ph17070902</pub-id><pub-id pub-id-type="pmid">39065752</pub-id><pub-id pub-id-type="pmcid">PMC11279923</pub-id></element-citation></ref><ref id="B59-pharmaceutics-17-01215"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haider</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jeppesen</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Josephson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>S.H.</given-names></name></person-group><article-title>Radiochemistry for positron emission tomography</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>3257</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-36377-4</pub-id><pub-id pub-id-type="pmid">37277339</pub-id><pub-id pub-id-type="pmcid">PMC10241151</pub-id></element-citation></ref><ref id="B60-pharmaceutics-17-01215"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leeb-Lundberg</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Marceau</surname><given-names>F.</given-names></name><name name-style="western"><surname>Muller-Esterl</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pettibone</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Zuraw</surname><given-names>B.L.</given-names></name></person-group><article-title>International union of pharmacology. XLV. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences</article-title><source>Pharmacol. Rev.</source><year>2005</year><volume>57</volume><fpage>27</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1124/pr.57.1.2</pub-id><pub-id pub-id-type="pmid">15734727</pub-id></element-citation></ref><ref id="B61-pharmaceutics-17-01215"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moller</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Moo</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Brauner-Osborne</surname><given-names>H.</given-names></name></person-group><article-title>Characterization of the real-time internalization of nine GPCRs reveals distinct dependence on arrestins and G proteins</article-title><source>Biochim. Biophys. Acta Mol. Cell Res.</source><year>2024</year><volume>1871</volume><elocation-id>119584</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbamcr.2023.119584</pub-id><pub-id pub-id-type="pmid">37714305</pub-id></element-citation></ref><ref id="B62-pharmaceutics-17-01215"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chigoho</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Bridoux</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hernot</surname><given-names>S.</given-names></name></person-group><article-title>Reducing the renal retention of low- to moderate-molecular-weight radiopharmaceuticals</article-title><source>Curr. Opin. Chem. Biol.</source><year>2021</year><volume>63</volume><fpage>219</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2021.06.008</pub-id><pub-id pub-id-type="pmid">34325089</pub-id></element-citation></ref><ref id="B63-pharmaceutics-17-01215"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erbas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tuncel</surname><given-names>M.</given-names></name></person-group><article-title>Renal Function Assessment During Peptide Receptor Radionuclide Therapy</article-title><source>Semin. Nucl. Med.</source><year>2016</year><volume>46</volume><fpage>462</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1053/j.semnuclmed.2016.04.006</pub-id><pub-id pub-id-type="pmid">27553471</pub-id></element-citation></ref><ref id="B64-pharmaceutics-17-01215"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vegt</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wetzels</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Masereeuw</surname><given-names>R.</given-names></name><name name-style="western"><surname>Melis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oyen</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Gotthardt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boerman</surname><given-names>O.C.</given-names></name></person-group><article-title>Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention</article-title><source>J. Nucl. Med.</source><year>2010</year><volume>51</volume><fpage>1049</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.2967/jnumed.110.075101</pub-id><pub-id pub-id-type="pmid">20554737</pub-id></element-citation></ref><ref id="B65-pharmaceutics-17-01215"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandes</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>de Matos Gomes</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sirois</surname><given-names>P.</given-names></name></person-group><article-title>The bradykinin B1 receptor antagonist R-954 inhibits Ehrlich tumor growth in rodents</article-title><source>Peptides</source><year>2011</year><volume>32</volume><fpage>1849</fpage><lpage>1854</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2011.07.023</pub-id><pub-id pub-id-type="pmid">21835216</pub-id></element-citation></ref><ref id="B66-pharmaceutics-17-01215"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cote</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tremblay</surname><given-names>L.</given-names></name><name name-style="western"><surname>Neugebauer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Regoli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gariepy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hebert</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gobeil</surname><given-names>F.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Safety and pharmacokinetics of a kinin B1 receptor peptide agonist produced with different counter-ions</article-title><source>Biol. Chem.</source><year>2016</year><volume>397</volume><fpage>365</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1515/hsz-2015-0246</pub-id><pub-id pub-id-type="pmid">26565554</pub-id></element-citation></ref><ref id="B67-pharmaceutics-17-01215"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>C&#244;t&#233;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Savard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neugebauer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fortin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lepage</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gobeil</surname><given-names>F.</given-names></name></person-group><article-title>Dual kinin B1 and B2 receptor activation provides enhanced blood-brain barrier permeability and anticancer drug delivery into brain tumors</article-title><source>Cancer Biol. Ther.</source><year>2013</year><volume>14</volume><fpage>806</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.4161/cbt.25327</pub-id><pub-id pub-id-type="pmid">23792591</pub-id><pub-id pub-id-type="pmcid">PMC3909549</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-01215-f001" orientation="portrait"><label>Figure 1</label><caption><p>(<bold>A</bold>) Expression of B1R in human PCa cell lines assessed by qPCR (<italic toggle="yes">n</italic> = 2&#8211;3). (<bold>B</bold>) B1R gene expression analysis of the human PCa cell line-derived xenografts (CDX) in Nu/Nu mice (four CDX models from Charles River). Affymetrix data are presented as log2 (GCRMA), with higher values indicating increased B1R expression. (<bold>C</bold>) B1R expression in clinical human PCa tissue samples (tumor and matched normal-adjacent; <italic toggle="yes">n</italic> = 14) analyzed by qPCR. * Indicates <italic toggle="yes">p</italic>-value &lt; 0.05 according to paired Student <italic toggle="yes">t</italic>-test. (<bold>D</bold>) Representative pictures taken from cores of normal, PIN, and Gleason 3&#8211;4&#8211;5 foci, and of metastatic PCa in peripancreatic ganglia. Magnification 20&#215;, scale bar represents 100 &#181;m. Semi-quantitative immunoscores (as per scoring scale shown in <xref rid="app1-pharmaceutics-17-01215" ref-type="app">Supplementary Figure S2</xref>) of normal (<italic toggle="yes">n</italic> = 95), PIN (<italic toggle="yes">n</italic> = 71), Gleason 3 (<italic toggle="yes">n</italic> = 126), 4 (<italic toggle="yes">n</italic> = 64), 5 (<italic toggle="yes">n</italic> = 18), * indicates <italic toggle="yes">p</italic>-value &lt; 0.05 and *** &lt;0.001 according to a one-way ANOVA with Tukey&#8217;s multiple comparison tests. (<bold>E</bold>) Histogram views and Pearson r correlation coefficients of hB1R gene expression according to tumor Gleason score from The Cancer Genome Atlas (TCGA) firehose legacy and the Memorial Sloan Kettering Cancer Center (MSKCC) 2010 datasets, both retrieved using cBioportal tool. ** Indicates <italic toggle="yes">p</italic>-value &lt; 0.01 according to Tukey&#8217;s multiple comparison tests. (<bold>F</bold>) Kaplan&#8211;Meier survival curves according to prostate cancer B1R (BDKRB1) mRNA expression levels for MSKCC Cancer Cell 2010 dataset (high and low, respectively &gt; or &lt;z-score 2.25 compared to normal tissues) and TCGA Firehose Legacy (high and low, respectively &gt; or &lt;z-score 1.75 vs. diploids) accessed by cBioportal. Log-rank test <italic toggle="yes">p</italic>-values are indicated within each graph.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01215-g001.jpg"/></fig><fig position="float" id="pharmaceutics-17-01215-f002" orientation="portrait"><label>Figure 2</label><caption><p>Chemical structure and metabolic stability of the novel B1R-targeting theranostic antagonist, <sup>64</sup>Cu/NOTA-&#946;Ala-R954. (<bold>A</bold>) Theranostic peptide sequence. (<bold>B</bold>) Radiolabeling of NOTA-&#946;Ala-R954 to <sup>64</sup>Cu. Representative radio-UPLC chromatograms are shown. (<bold>C</bold>,<bold>D</bold>) Radiolysis evaluation of <sup>64</sup>Cu/NOTA-&#946;Ala-R954 at time point 0 and 24 h assessed by radio-UPLC and radio-TLC, respectively. Representative experiments are shown. (<bold>E</bold>) Ex vivo metabolic stability of <sup>64</sup>Cu/NOTA-&#946;Ala-R954 following a 24 h incubation at 37 &#176;C in undiluted mouse and human plasma. Representative radio-UPLC chromatograms are shown (<italic toggle="yes">n</italic> = 2). (<bold>F</bold>) UPLC radiometric chromatogram illustrating the complete in vivo stability of the <sup>64</sup>Cu/NOTA-&#946;Ala-R954 (appearing as an intact form&#8212;single peak&#8212;in blood and urine extracts) following I.V. injection in normal mice. Blood and urine were collected 90 min after bolus I.V. administration (<italic toggle="yes">n</italic> = 2).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01215-g002.jpg"/></fig><fig position="float" id="pharmaceutics-17-01215-f003" orientation="portrait"><label>Figure 3</label><caption><p>Cellular uptake, nuclear distribution, and anticancer activity of <sup>64</sup>Cu/NOTA-&#946;Ala-R954 in PCa cells. (<bold>A</bold>) Time-course analysis of <sup>64</sup>Cu-NOTA-&#946;Ala-R954 (10 KBq; 0.5 &#181;M) incorporation by PCa PC3 cells. *** <italic toggle="yes">p</italic>-value &lt;0.001 vs. 0.25 h timepoint, according to multiple <italic toggle="yes">t</italic>-tests, <italic toggle="yes">n</italic> = 4; <sup>ttt</sup>&#160;<italic toggle="yes">p</italic>-value &lt; 0.001 vs. 24 h time-point; unpaired Student&#8217;s <italic toggle="yes">t</italic>-tests. (<bold>B</bold>) Cell uptake of <sup>Nat</sup>Cu-NOTA-&#946;Ala-R954 (0.5 &#181;M) in PC3 cells at 24 h post-treatment, as determined by ICP-MS. * <italic toggle="yes">p</italic> &lt; 0.05 according to multiple <italic toggle="yes">t</italic>-tests (<italic toggle="yes">n</italic> = 7&#8211;8 assays). (<bold>C</bold>) Intracellular/nuclear distribution of <sup>64</sup>Cu-NOTA-&#946;Ala-R954 (10 KBq; 0.5 &#181;M) in PC3 cells at 24 h post-treatment (<italic toggle="yes">n</italic> = 4 experiments). Validation of the purity of nuclear fractions extracted from PC3 cells by immunoblotting using organelle-specific marker proteins (<bold>left</bold>) and by optical microscopy after trypan blue staining (<bold>upper right</bold>). (<bold>D</bold>) Dose-dependent antiproliferative effects of <sup>64</sup>Cu/NOTA-&#946;Ala-R954 on PCa LNCaP and PC3 cells using clonogenic assays. * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01 vs. control, according to one-way ANOVA followed by Dunnett&#8217;s multiple comparison, <italic toggle="yes">n</italic> = 4 experiments. No inhibitory effects of the non-radioactive <sup>Nat</sup>Cu/NOTA-&#946;Ala-R954 (10 &#181;M) on PC3 and LNCap cell growth and clonogenic potential.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01215-g003.jpg"/></fig><fig position="float" id="pharmaceutics-17-01215-f004" orientation="portrait"><label>Figure 4</label><caption><p>Efficacy of <sup>64</sup>Cu/NOTA-&#946;Ala-R954 for detecting PCa by PET imaging. (<bold>A</bold>) Biodistribution of intravenous <sup>64</sup>Cu/NOTA-&#946;Ala-R954 (5&#8211;10 MBq) in normal male BALB/c mice at 1 and 4 h post-injection (p.i.) (<italic toggle="yes">n</italic> = 4 mice per group). (<bold>B</bold>) Representative micro-PET images of PC3 tumor-bearing nude mouse acquired 1 h post-injection of <sup>64</sup>Cu/NOTA-&#946;Ala-R954 (7 MBq) using a LabPET8 scanner (<bold>left</bold>). Tumors are indicated by yellow arrows. Histographic representation of calculated ID/g (%) values of intravenous <sup>64</sup>Cu/NOTA-&#946;Ala-R954 (6&#8211;7 MBq) at 1 h post-injection in PC3 tumor-bearing nude mice pretreated (10 min before) or not with R954 (0.5&#8211;1 mg/kg) (<bold>right</bold>). Mean &#177; SEM are shown; <italic toggle="yes">n</italic> = 4 tumors from 2 to 3 mice, ** <italic toggle="yes">p</italic> &lt; 0.01 vs. corresponding blockade group, using unpaired two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test. IHC confirmed high expression of B1R in harvested tumoral tissues of PC3-bearing mice (<bold>upper-right panel</bold>). IHC staining of B1R was performed on 5 &#181;m thick sections of formalin fixed/paraffin-embedded tissues from subcutaneous PC3 human xenograft tumors in athymic nude mice. IHC analysis was performed using the anti-hB1R antiserum AS434 (1:500 dilution). Negative control with rabbit pre-immune serum (1:500) showed no staining. Nuclei were counterstained with hematoxylin. Optical magnification is indicated in the bottom-left corner of each image. (<bold>C</bold>) PC3 tumor-to-normal-organ ratios for <sup>64</sup>Cu/NOTA-&#946;Ala-R954 (~6&#8211;7 MBq) at 1 h and 20 h post-injections. Mean &#177; SEM are shown; <italic toggle="yes">n</italic> = 4 tumors from 2 to 3 mice. * <italic toggle="yes">p</italic> &lt; 0.05 vs. corresponding ratio at 1 h, using Mann&#8211;Whitney U test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01215-g004.jpg"/></fig><fig position="float" id="pharmaceutics-17-01215-f005" orientation="portrait"><label>Figure 5</label><caption><p>Comparison of the anticancer efficacy of a single-dose IV <sup>64</sup>Cu/NOTA-&#946;Ala-R954 (50 &#181;g/kg; 65 MBq) and <sup>Nat</sup>Cu/NOTA-&#946;Ala-R954 (50 &#181;g/kg) in nude mice bearing s.c. PC3 xenografts. (<bold>A</bold>) Normalized tumor growth following treatment. Data represent the mean &#177; SEM from 14 to 16 tumors per group (<italic toggle="yes">n</italic> = 8&#8211;9 mice/group); ** <italic toggle="yes">p</italic> &lt; 0.01, *** <italic toggle="yes">p</italic> &lt; 0.001 vs. CTL, using unpaired Student&#8217;s <italic toggle="yes">t</italic>-test with Welch correction. (<bold>B</bold>) Changes in body weight of animals after treatments. (<bold>C</bold>) Expression levels of active caspase-3 (apoptotic), Ki67 (proliferative), CD34 (angiogenic), and LYVE-1 (lymphatic) biomarkers in PC3 tumors. Representative micrographs of tumor sections are shown for control (saline) and PRRT-treated groups (<bold>left</bold> and <bold>right panels</bold>, respectively). Histograms depict quantitative analysis of marker expression, presented as mean &#177; SEM from 6 to 8 tumors per group (<italic toggle="yes">n</italic> = 3 mice). ** <italic toggle="yes">p</italic> &lt; 0.01, *** <italic toggle="yes">p</italic> &lt; 0.001 vs. CTL, using unpaired two-tailed Student&#8217;s <italic toggle="yes">t</italic>-tests.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01215-g005.jpg"/></fig><table-wrap position="float" id="pharmaceutics-17-01215-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01215-t001_Table 1</object-id><label>Table 1</label><caption><p>Binding affinity, selectivity, and potency estimates of a novel NOTA-R954 peptide conjugate at recombinant (HEK293, CHO) and native (HUV) human kinin B1R and B2R.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
Sequence
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
B1R
<break/>
HEK293
<break/>
IC<sub>50</sub> (nM)
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
B2R
<break/>
HEK293
<break/>
IC<sub>50</sub>
<break/>
(&#181;M)
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
B1R-NFAT CHO
<break/>
Kb
<break/>
(nM)
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
B1R
<break/>
HUV
<break/>
IC<sub>50</sub>
<break/>
(nM)
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
B2R
<break/>
HUV
<break/>
IC<sub>50</sub>
<break/>
(&#181;M)
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ac-Orn-Arg-Oic-Pro-Gly-(&#945;Me)Phe-Ser-D&#946;Nal-Ile-OH (R954)</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;10</td><td align="center" valign="middle" rowspan="1" colspan="1">1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;10</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NOTA-&#946;Ala-Orn-Arg-Oic-Pro-Gly-(&#945;Me)Phe-Ser-D&#946;Nal-Ile-OH</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;10</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;10</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><sup>Nat</sup>Cu/NOTA-&#946;Ala-Orn-Arg-Oic-Pro-Gly-(&#945;Me)Phe-Ser-D&#946;Nal-Ile-OH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;10</td></tr></tbody></table><table-wrap-foot><fn><p>Binding affinities of compounds were expressed in terms of IC<sub>50</sub> values. Data are means of 2 independent experiments performed in triplicates. For in vitro functional studies (CHO-eGFP/NFAT reporter cells), competitive antagonist affinity estimates (Kb) were obtained from complete agonist concentration&#8211;response curves using the Schild simplified Gaddum&#8217;s equation: Kb = [B]/(concentration-ratio&#8211;1), [B]: antagonist concentration, concentration ratio: EC<sub>50</sub> of agonist + antagonist/EC<sub>50</sub> of agonist alone. Data represent means from a single experiment performed in triplicates. For ex vivo experiments (HUV contractile bioassays), data are means of 2 independent experiments.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>